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ABSTRACT 
Three DNA extraction methods applied on 20 parafFin-embedded tissues were 
、compared for their extraction efficiency for human DNA and human papillomavirus 
(HPV) DNA. Among each extraction method, the overall beta-globin PCR positive 
rates were similar. For HPV PCR (450-bp), the positive rates increased from 20% in 
phenol-chloroform to 67% in microwave and 90% in QIAGEN spin column 
extraction. QIAGEN spin column was found to be the most superior method and also 
showed the highest positive predictive value with 90% of 509-bp beta-globin positive 
samples yield an expected size ofHPV DNA. The results also suggest that previous 
studies using phenol-chloroform extraction might have underestimated the 
prevalence ofHPV. Furthermore, for some extraction methods, using house-keeping 
gene PCR may not reflect the quality ofHPV DNA extraction. 
The prevalence and genotype distribution ofHPVs among 593 Chinese women 
with normal cervices and 440 with abnormal cervical cytologies were determined by 
PCR and restriction fragment length polymorphisms. The overall HPV positive rates 
were 4.2% (25/593) and 45.2% (199/440) respectively. In women with normal 
cervices, the uncharacterized HPV types were the most commonly detected HPV 
genotypes. Among women with abnormal cervical cytologies, HPV was detected in 
15.5% of normal or inflamed cervix, 28.3% of condyloma, 61.9% of Cervical 
Intraepithelial Neoplasia 1 (CEM 1), 61.6% o f O N 1, 69.2% o f O N 3 and 70.8% of 
cervical carcinoma. In women with high-grade cervical lesions, HPV 16 was the 
most predominant type (58/126), followed by HPV 58 (21/126). The presence of 
HPV 16, 33 and 58 showed a statistically significant increase in risk for high-grade 
cervical lesions {P < 0.05 by f test). Among women with abnormal cytologies, HPV 
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16 also showed a specificity of 96.4% and a positive predictive value of 86.6% for 
high-grade cervical lesions. The overall results reveal that an intermediate-risk HPV 
type 58 exists with an unusual high prevalence among our local Chinese women with 
、high-grade cervical lesions. In contrast, HPV 58 is reported only in 2% of women 
with cervical cancer worldwide. 
Seven patterns of HPV 16 E7 sequences were identified from the studied 92 
samples. Twenty-seven samples showed a "prototype-like" sequence that was 
identical to the prototype HPV 16. For "HPV 16 E7 HK-1", "HPV 16 E7 HK-2" and 
"HPV 16 E7 HK-3" variants, mutations were found to be located closely to the pRb 
binding and casein kinase II phosphorylation site, whereas mutations located at the 
Cys-X-X-Cys motifwere observed in "HPV 16 E7 HK-6". "HPV 16 E7 HK-3" was 
most commonly found in women with high-grade cervical lesions (78.6%). In the 
low-grade cervical lesions group, 14 samples (77.8%) showed one of the variants and 
four (22.2%) with "prototype-like". For the high-grade cervical lesions group, 51 
(68.9%) showed variants and 23 (31.1%) with “prototype-like” However, none of 
the variants showed a significant association with the degree of cervical lesion. 
Nevertheless, this does not negate an association between HPV 16 E7 sequence 
variation with the development of cervical cancer. Further studies with more samples 
and taking other cofactors, in particular immunogenetics into account is required. 
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1.1 Biology ofHuman Papillomaviruses 
、 
LL1 Taxonomy 
Human papillomaviruses (HPVs) have been classified as members of the 
Papovaviridae family, which consists of the Polymavirus genus and the 
Papillomavirus genus. HPV DNA study was first reported in 1965 (Crawford, 1965) 
and with the advent of molecular virology and cloning in the 1970's, to date, more 
than 85 distinct HPV types have been isolated and characterized (Munoz and Bosch, 
1992; Zur Hausen and De Villiers, 1994; Van Ranst et al., 1996). 
1.1.2 Genomic Organization 
The genome of HPV consists of a supercoiled, circular double-stranded DNA 
with a length ofabout 8000 base pairs. HPVs are small, non-enveloped particles with 
diameters around 55 nm and their nucleocapsid are icosahedral with 72 capsomers 
arranged on the surface with a triangulation number of seven. The general 
organisation of the genome is the same for different HPV types and it is divided into 
early and late regions, encoding seven early and two late genetic opening reading 
frames. The early genes are responsible for viral replication, transcriptional control 
and cellular transformation whereas the late genes are for encoding viral structural 
proteins of the virus particles. Besides, there is a noncoding region called the 
upstream regulatory region that contains sequences for regulating the expression of 
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the early and late open reading frames. 
The HPV early genes have multiple functions. The E l and E2 genes are involved 
、in viral replication and transcriptional control respectively (Chiang et al., 1992; 
Scheffner et al., 1994; Sverdrup and Kahn, 1994; Lewis et al., 1999). The E2 region 
is often disrupted during viral integration. El proteins are involved in genome 
maintenance and replication through ATPase and helicase activity. E l has been 
shown to bind to the full length ofE2 protein and results in strengthening the affinity 
o fE l for the origin o fDNA replication (Storey et al., 1995). For the E2 proteins, 
they ftmction as transcriptional modulators and consist of three functionally different 
domains in which the amino-terminal and carboxy-terminal are highly conserved 
among all E2 proteins. The amino-terminal has a transcription activation domain and 
the carboxy-terminal contains a DNA binding domain (Dowhanick et al., 1995). The 
E2 open reading frame encodes the major regulatory proteins that interact with the 
upstream regulatory region, have both positive and negative effects on viral 
transcription (McBride et al., 1991). The E2 transcription transactivator activates the 
viral promoters by binding to E2-responsive enhancer elements while the E2 
transcription repressor represses such function. On the other hand, E2 has an 
important transcriptional regulatory function for the E6 and E7 promoters. It has 
been reported that the E2 proteins act as repressor for the E6 and E7 promoters 
(Francis et al., 2000; Nishimura et al., 2000), and mutations in the E2 open reading 
frame increase the expression of the E6 and E7 oncoproteins. Integration often leads 
to a disruption of the early coding region located between the El and E2 open 
reading frames (Kalantari et al., 1998). In integrated viral DNA, there is a loss of 
both types of E2 proteins that involved in transactivation and repression. 
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Consequently, viral integration relieves the repressing function of the E2 proteins, 
which in tum favors the expression of HPV E6 and E7 oncoproteins (Jeon and 
Lambert, 1995; Frattini et al., 1997). 
> 
The E5, E6 and E7 open reading frames encoded proteins are all involved in 
cellular transformation (Sedman et al., 1991; Banks and Matlashewski，1993; 
Munger and Phelps, 1993). Protein encoded by the E5 gene has only weak 
transforming properties and is involved in cell transformation through the stimulation 
of the growth factor receptor signal transduction pathways and the activation of the 
platelet-derived growth factor receptor (Leechanachai et al., 1992; Johnsen et al., 
1995). Since the E6 and E7 genes are the major oncogenes encoded by the human 
papillomavirus, the functions ofE6 and E7 oncoproteins will be further elaborated in 
later sections. 
The function of the late genes of HPV, L1 and L2, is to encode the major and 
minor structural capsid proteins. For the L1 gene, there is a broad genetic diversity in 
the L1 open reading frame among different HPV types. For the L2 protein, it 
represents about 10% of the total protein content of the HPV particles. 
LL3 Types, Subtypes and Variants 
All HPVs have a similar structure and genomic organisation. Given the lack of 
reagents for serotyping as HPV cannot be grown on conventional tissue culture and 
cannot be transmitted to laboratory animals, HPVs are classified according to their 
genomic sequence similarities rather than by classical serology. Historically, HPV 
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type is classified based on sequence homology by using liquid hybridisation and 
reassociation kinetics (Coggin and Zur Hausen, 1979). Subtype is defined according 
to variations in the restriction endonuclease digestion patterns distinct from the HPV 
、prototype patterns, while HPV variant is classified by the presence of an undefined 
but limited number of nucleotide differences. Related HPVs with less than 50% 
cross-hybridisation to an established HPV are classified as a unique type and given a 
new number in the order of acceptance by the Nomenclature Committee established 
at the German Cancers Research Centre, Heidelberg. More recently, the definition of 
a new HPV type is defined as one that has been completely cloned and whose E6, L1 
and upstream regulatory regions should demonstrate less than 90% nucleotide 
sequence identity with previously typed papillomaviruses (Van Ranst et al., 1993). A 
similar quantitative definition for subtypes and variants are used in which a subtype 
should have 90% to 98% homology with an established HPV type, and a variant as 
sharing more than 98% homology within the E6, L1 and upstream regulatory regions 
(Van Ranst et al., 1993). 
To group the large number ofHPV types, phylogenetic tree is constructed based 
on nucleotide and amino acid sequence alignments of the E6 genes. For instance, 
HPV intratypic-variation that has been most extensively studied was HPV 16 (Ho et 
al., 1991; Chan et al., 1992; Yamada et al., 1997). Phylogenetic studies have 
distinguished five major branches ofHPV 16: AA (Asia-American), As (Asian), Afl 
(African-1), Af2 (African-2) and E (European) (Ho et al., 1993). The As and E 
branches are closely related that the As seems to be a subclass of E lineage. For the 
remaining three branches, they are well separated from each other. Minor branches 
are further identified and are defined as AA-G131/AA-c, E-G131 and NA1 O l^orth 
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American 1) (Yamada et al., 1997). 
For the studies of HPV variants, focus has been on establishing their inter- and 
、intratypic- phylogenetic relationships based on nucleotide sequence analysis ofHPV 
6, 16 and 18 (Ong et al., 1993; Yaegashi et al, 1993; Wheeler et al., 1997). Extensive 
studies on the sequence variation within the L1, L2, E2, E6 and E7 open reading 
frames reveal that certain sequence-specific changes can alter the biological 
functions ofthe human papillomavirus such as its ability to transform cells and thus 
its carcinogenic potential (Icenogle et al., 1991; Yamada et al., 1995). 
1.2 Epidemiology of Cervical Cancers 
About 85-90% ofcervical cancers are squamous cell carcinoma. The remaining 
10-15% is adenocarcinoma and they develop from the mucus-producing gland cells 
ofthe endocervix (Schiffman and Brinton, 1995). Cervical cancers have its origins at 
the squamous—columnar junction in the endocervical canal of the cervix within the 
transformation zone (Park et al., 1992). This zone is the area of the cervix that was 
originally covered with columnar epithelium, which, through a physiologic process 
known as metaplasia, becomes squamous epithelium. The outer border of the 
transformation zone is the original squamocolumnar junction and the inner border is 
the existing squamocolumnar junction. Virtually all cervical precancers and cancers 
originate in this zone, at the squamocolumnar junction during the metaplastic 
process. 
Cervical cancers have a precursor lesion called dysplasia or cervical 
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intraepithelial neoplasia (CES[) as classified according to the Bethesda System 
(Kurman and Solomaon, 1994; Jones, 1995) which can subsequently become 
invasive cancers (Park et al., 1992). The Bethesda System combines similar 
intraepithelial diagnosis into broad categories including low-grade squamous 
intraepithelial lesions and high-grade squamous intraepithelial lesions. The 
distinction between these squamous intraepithelial lesions is important for the study 
of cervical carcinogenesis. 
Low-grade squamous intraepithelial lesions refer to early changes in size, shape 
and number of cells that form the surface of the cervix. Some low-grade lesions 
regress on their own. However, with time, others may grow larger or become more 
abnormal, forming high-grade lesions. In the case of precancerous low-grade lesions, 
they are known as mild dysplasia or CJN 1. Such early occurrence of precancerous 
low-grade lesions in the cervix happens most often in women between the ages of 25 
and 35, but can appear in other age groups as well (Morrison, 1994). 
High-grade squamous intraepithelial lesions refer to a large number of 
precancerous abnormal cells on the surface of the cervix. These cells usually do not 
become cancerous or invade the deeper layer of the cervix until many months or 
years later. High-grade lesions comprise of moderate or severe dysplasia, called 
cervical intraepithelial neoplasia 2 (CrN 2) and cervical intraepithelial neoplasia 3 
(CIN 3). CW 2 and CES[ 3 are distinguished by increasing nuclear atypia and failure 
of cellular differentiation in the superficial levels of the epithelium, full-thickness 
replacement with undifferentiated, immortalised atypical cells. High-grade squamous 
intraepithelial lesions can develop at all ages, most often in women between the age 
7 
of30 and 40. Ifthe abnormal cells spread deeper into the cervix or to other tissues or 
organs, it becomes invasive cervical cancer, which tends to occur in women with the 
age over 40. 
l,2A Incidence 
Epidemiology is the study of the relationships of various factors determining 
. the frequency and distribution of diseases in the human population. The incidence 
rates for cervical cancers are high, an estimated 500,000 women worldwide are 
diagnosed each year as having cervical cancers (Schoell et al., 1999) and is the most 
frequent cancer among women in developing countries, especially in Africa, Asia 
and South America. The mortality associated with this malignancy is only exceeded 
by that of breast cancer and ranks as the second leading cause of cancers in women 
(Herrero et al., 1992). In United States, where screening for cervical cancers is 
readily available, the incidence and mortality rates are low with an estimated 13,700 
new cases of invasive cancers of the cervix and 4,900 deaths each year (Brinton, 
1992). However, cervical cancer is about twice as common in Asia as in the Westem 
world and its incidence varies among different Asian ethic groups. In Taiwan, 
cervical cancer is now the leading cancer incidence and the third leading cancer 
death among women, with an incidence and mortality rate of 23.7 and 6.15 
respectively per 100,000 population (Pao et al., 1993). Cervical cancer is relatively 
common in China and an extremely high incidence of cervical cancer is observed in 
Shanghai with an incidence rate of 1026 and mortality rate of 54.5 per 100,000 
population (Pao et al., 1993). h\ Hong Kong, cervical cancer ranks the seventh for 
cancer death in women with a mortality rate of3 .6 per 100,000 population. There are 
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about 500 new cases diagnosed annually, and approximately 150 women die from 
cervical cancers. The median age at diagnosis is 56 years with an age-standardised 
rate of 12.7 per 100,000 population (Hong Kong Cancer Registry, 1996; Chan, 
、1998). 
Cervical cancers have several well-established epidemiological risk factors, 
including smoking, use of oral contraceptives, socioeconomic status, age, race, 
multiple sex partners, and nutritional factors (Bosch et al.，1992; Cuzick et al., 1996; 
Ho et al., 1998b; Kjellberg et al., 2000). All of these have been suggested to increase 
a woman's risk of developing cervical cancers. Cigarette smoking may slightly 
increase the risk for squamous cell carcinoma and the longer the duration and 
intensity of smoking, the higher the risk for developing cervical cancers (Slattery et 
al., 1989; Bosch et al., 1994). Long-term use of oral contraceptives for more than 
five years may contribute to the development of cervical cancers, particular of 
adenocarcinoma (Hildesheim et al., 1990; Brinton, 1992; Ylitalo et al., 1999). 
Women in low social classes or with an age above 60 may be at increased risk for 
cervical cancers as they have low education level, and less willing or able to seek 
medical care (Hildesheim et al., 1993). In United States, there are differences in 
incidence rates with respect to races (Sideri et al., 1998) in which the blacks and 
Hispanics women have a higher rate than the Whites or Orientals. Multiple sex 
partners has also been implicated as a risk factor (Kjaer et al., 1998; Svare et al., 
1998) and women with poor diets may be at increased risk for cervical cancers 
(Kantesky et al., 1998). Still no definite evidence exists linking all these risk factors 
with the development of cervical cancers and available studies yield contradictory 
results. 
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1.2.2 Cervical Cancers Screening Programme 
Most cervical cancers have a long pre-invasive stage and the precancerous 
、changes of the cervix usually do not cause pain or any symptoms and are not 
detected unless a woman has a cervical screening or a Papanicolaou (Pap test). The 
Pap test is a simple, painless test to detect abnormal cells in and around the cervix. It 
is used as a screening tool that identifies women likely to have premalignant disease 
that are at higher risk for cervical cancers. The incidence of cervical cancers is very 
low in countries that have good Pap smear screening programme such as in the 
United States, where the incidence of cervical cancers fell by 70% after Pap smear 
screening had started (Koss, 1989). Mortality from cervical cancers has also 
decreased in several large populations following the introduction ofwell-run cervical 
screening programmes (Benedet et al., 1992; Siguurdsson, 1993). Reductions in 
incidence and mortality seem to be proportional to the intensity of the screening 
efforts. In Iceland, with its highest rates of screening activities, there has been the 
greatest reduction in mortality over the last 20 years when compared to those 
countries with lower rates of screening (Siguurdsson, 1993). From some case-control 
study, the risk of developing invasive cervical cancers is 10 times greater in women 
who have not been screened (Herrero et al., 1992). Risk also increases with longer 
duration following the last normal Pap smear or with decreasing frequency of 
screening. In Hong Kong, the percentage of women who have a Pap test is estimated 
to be very low and the incidence and mortality rates of cervical cancers are still at a 
considerable level (Chan, 1998). To reduce the incidence of cervical cancers, the 
cervical screening coverage should be increased. 
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1.3 Association between Human Papillomavirus and Cervical Cancers 
Epidemiological and molecular studies conducted over the last 20 years led to 
the recognition of specific types of HPVs as the aetiological agents of cervical 
cancers (Franco et al., 1999; Lazo, 1999). Not only have numerous epidemiological 
studies demonstrated that HPV infection is a strong risk factor for precancerous 
lesions and cervical cancers, but also numerous biological data have demonstrated 
the oncogenic potential ofHPVs (SchifFman et al., 1993; Schoell et aL, 1999). It has 
recently become apparent that HPV infection is highly prevalent in the general 
population, including a substantial number of cytologically normal women 
(Walboomers et al., 1999). Understanding the natural history of HPV infection, 
including the spectrum of HPV-associated disease and its prevalence in the general 
population as well as the molecular biology of HPVs has important implications in 
the prevention of cervical cancers. Independent of other risk factors, the overall 
evidence indicates that certain HPVs is the aetiology of precancerous lesions of the 
cervix and cervical cancers (Schiffman et al., 1993). 
1.3.1 Infection 
Numerous studies suggest that cervical cancer arises from long standing, HPV-
related precancerous lesions called cervical intraepithelial neoplasias. It is now 
widely appreciated that cervical cancers and cervical intraepithelial neoplasias are 
associated with HPV infection and their association is very strong (Koutsky et al., 
1992; Kjaer et al., 1996; Chang et al., 1997). HPV infection tends to precede and 
predict the occurrence of cervical intraepithelial neoplasias. Results from large 
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prospective studies of cytologically normal women show an elevated relative risk of 
c m 1 and CW 2 within a few years after HPV infection (Hsing et al., 1994). 
Besides, detectable HPV DNA can be found in a majority of women with cervical 
intraepithelial neoplasias and cervical cancers. The cancers-associated HPV types, 
particular HPV types 16 and 18, predict a higher risk of progression to CJN 3 or 
cervical cancers (Lombard et al.，1998; Takac et al., 1998). 
There are at least 28 types that have been found in female genital tract infection 
causing genital warts, cervical intraepithelial neoplasia and cervical cancers. In this 
mucosotropic group of HPVs, they are further classified into low-risk, intermediate-
risk and high-risk groups based on their occurrence and potential for progression to 
cancers (Lungu et al., 1992). The low-risk HPVs are defined by the fact that they are 
only rarely associated with high-grade cervical intraepithelial neoplasia and invasive 
cancers. The most common low-risk HPV types 6 and 11 primarily causing benign 
warts, are present in condyloma and CJN 1. These two HPV types have been 
identified in the majority of condylomata acuminatum and CrN 1，but are rarely in 
precanceous cervical lesions and cervical cancers. The intermediate-risk types, HPV 
types 31, 33, 35, 45, 51, 52, 56, 58 and 59 have been shown to occur in all grades of 
cervical intraepithelial neoplasias and occasionally in cervical cancers. High-risk 
HPV types 16, 18 and 45 are closely associated with the entire range of cervical 
intraepithelial neoplasia and are most often found in CJN 3 and invasive cancers 
(Schiffman and Brinton, 1995). HPV 16 and HPV 18 have been found frequently in 
cervical cancers. HPV 16 is the type mostly associated with squamous cell 
carcinoma, whereas HPV 18 is often identified in adenocarcinoma and 
adenosquamous carcinoma (Virtej et al., 1998). Several studies have documented a 
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higher prevalence of HPV 16 in CJN 2 or CJN 3 than in CIN 1 or condylomata 
acuminatum. Still many cases have reported many unknown HPV types, which are 
also strongly related to cervical cancers (Peyton et al., 1994; Meyer et al., 1998). 
.、. 
I.J.2 Multistep Pathogenesis of Cervical Cancers 
HPV infection ofthe uterine cervix first occurs in the basal epithelial cells. The 
HPV-infected basal epithelial cells can have one of the several outcomes. In an 
active or production infection, propagation ofHPV inside the cell leads to cell lysis 
and the release of free viral particles. Alternatively, HPV may also enter the latent 
phase without replication. Some of these latent infections may result in integration of 
HPV DNA into the host genome and this is considered to be a prerequisite for HPV-
induced carcinogenesis. 
Cervical cancers do not form suddenly and there is a gradual change from 
normal cervix to precancers and even takes years to invasive cancers. Many factors 
are thought to induce dysplasia. Infection with HPV is undoubtedly by far the most 
common (Zur Hausen, 1991). Dysplasia develops in a high percentage of women 
with HPVs detected on their cervices and these lesions can persist, regress, or 
progress to an invasive malignancy. However, factors that govem regression, 
persistence and progression of squamous intraepithelial lesion are still poorly 
understood (Cox, 1995). It has been shown that for women aged between 25 to 45 
years who demonstrate abnormalities and the presence ofHPV DNA, the mean time 
for progression is about four years (Konno et al., 1998). For women with low-grade 
squamous intraepithelial lesion (CrN 1), it often regresses to normal without 
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treatment. Only about 20% of low-grade squamous intraepithelial lesion progress to 
more severe stage of high-grade squamous intraepithelial lesions (CE^ 2 and CESf 3) 
and the average time for progression of CJN 3 to invasive cancers has been estimated 
to be 10 to 15 years (Remmink et al., 1995; Arends et al., 1998). 
L3.3 Geographical Distribution 
The average annual incidence of cervical cancers varies widely by geographic 
area. The highest rates have been reported from Latin America, where the risk is 
about six times that of US Whites, whose rate is one of the lowest in the world. In 
Asia, cervical cancer is about twice as common as in Europe and North America 
(Cuzick et al., 1989). In worldwide HPV prevalence studies, most cervical cancers 
have been found to contain the high-risk HPV types as the predominant types. The 
most recent international study of the geographic variation in the distribution ofHPV 
types includes more than 1000 cervical samples from over 20 countries and test for 
all known HPV types by PCR (Bosch et al., 1995). More than 85% of cervical 
cancers from each country contain HPV DNA in which there is no significant 
variation in HPV positivity among countries. Result showed that HPV 16 accounts 
for the highest proportion within the tested samples, followed by HPV 18, HPV 45 
and HPV 31 and the association with these HPV types is very strong and consistent. 
HPV 16 is the predominant type in all countries except Indonesia, where HPV 18 is 
more common. Besides, a significant geographic variation in the prevalence of some 
less common HPV types is found. HPV 45 is apparent in Westem Africa, while HPV 
39 and HPV 59 are almost entirely confined to Central and South America. In case-
control studies conducted in Taiwan, HPV 52 and HPV 58 are the most common 
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HPV types among HPV-positive Chinese women (Liaw et al., 1995; Huang et al., 
1997; Linetal.，1998). 
L3,4 Age Distribution ofHPVInfection 
Exposure to HPV is an extremely common event in young sexually active 
women. Indeed, a recent cross-sectional study on university student demonstrates 
that the prevalence of HPV among this sexually active group is 46% (Ho et al., 
1998a). It is also apparent that HPV DNA can be detected in many cytologically 
normal women with an estimate ofHPV prevalence range between 10% to 30 %, due 
to different detection methods used and the age of the population under study 
(Rakoczky et al., 1990; Melkert et al., 1993). Several investigators have found the 
presence ofHPV in cytologically normal women who are aged above 35 (De Villiers 
et al., 1987). Various prevalence estimates have been reported for HPV infection in 
different age groups. In a cohort study of over 8000 women with normal Pap smear 
showed that the highest HPV rate was found in the age group between 20-25 (De 
Villiers et al., 1992) and with a constant decline with increasing age to above age 55. 
Another study also revealed that the prevalence of cervical HPV infection declined 
sharply with age, with peak prevalence at aged 18-28 (Koutsky, 1997). 
1,3,5 Oncogenic Property ofHPV 
Viral regulatory mechanism may be altered by the disruption of E2 open 
reading frame during the process of integration. Integration of the high-risk HPV 
DNA is found most frequently in invasive cancers and to a variable degree in 
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precancerous lesions (Kalantari et al., 1998). The HPV DNA usually disrupted in a 
specific region after integration into the host genome, in particular, the E2 open 
reading frame, function in encoding the transcription regulatory proteins and 
、represses the expression ofE6 and E7 open reading frames. As the regulatory control 
oftranscription by E2 is lost, its ability to repress E6 and E7 open reading frames is 
no longer present which results in an uncontrolled production of E6 and E7 
oncoproteins. For the low-risk HPV types, no such integration is found and the E2 
regulation of the transcription and repression on E6 and E7 open reading frames are 
still permitted with intact episomal HPV genome. 
The HPV E6 and E7 open reading frames possess transformation potential and 
are related to HPV-associated carcinogenesis (Barbosa et al., 1991; Pinion et al., 
1991; Pillai et al., 1998; Song et al., 2000). The E6 and E7 oncoproteins can alter the 
fundamental cellular events such as cell cycle progression and apoptosis. The 
functions of E6 and E7 are involved in the inactivation of tumour suppression gene 
p53 and pRb respectively, which allows the survival and abnormal proliferation of 
the HPV infected-cells. The interaction of E6 and p53 results in the degradation of 
p53, whereas E7 and pRb interaction will lead to the destabilisation of cell cycle 
control (Amortegui et al., 1995; Kubbutat and Vousden, 1996; Lee et al., 1998; 
Zimmermann et al., 1999). 
The E6 open reading frame encodes multifunctional proteins, which are involved 
in transformation and immortalization (Band et al., 1991; Huibregtse and Beaudenon, 
1996; Liu et al., 1999; Song et al., 1999). The E6 protein can bind to and target the 
tumour suppressor protein, p53, for ubiquitin-dependent degradation (Werness et al., 
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1990; Josefsson et al., 1998; Rapp and Chen, 1998; Sonoda et al., 1999). The p53 
gene is the most commonly mutated gene in human cancers and is a negative 
regulator ofcell growth. It is also a transcription factor and is thought to mediate G1 
、arrest via induction of the p21 gene, which encodes an inhibitor of cyclin-dependent 
kinase. Growth arrest signals such as DNA damage or when the cell is under stress, 
the level ofp53 will increase, which led to cell cycle arrest and apoptosis. However, 
in an E6 expressing cell, E6 oncoproteins of high-risk HPV types bind and degrade 
p53 through ubiquitin-dependent pathway. This binding permanently removing the 
tumour suppression gene from its important regulatory role in the maintenance of 
genomic stability and result in an uncontrolled progression of the cell cycle which 
lead to cervical cancers (Thomas et al., 1999). 
The E7 oncoprotein also possesses the transformation properties and can 
transform rodent cells and immortalise human keratinocytes through the interaction 
of E7 oncoproteins with the tumour suppression protein pRb (Stoppler et al., 1998; 
Rey et al., 2000). For the pRb, in the normal stage, it is bound to the transcription 
factor, E2F resulting in the suppression of gene expression responsible for the G1 to 
S-phase progression. Mammalian cells become committed to cell division at a point 
in the mid-Gl-phase, following phosphorylation of the retinoblastoma proteins. pRb 
is inactivated by phosphorylation of both cyclin-dependent kinase complexes and 
result in the releases the E2F, which is required for transactivation of S-phase genes. 
The effect of high-risk HPV types E7 oncoproteins on the cell cycle pathway is 
involved in the Gl-S phase transition. E7 binds to pRb, causing pRb inactivation and 
the release of E2F, thus bypassing the requirement for cyclin-dependent kinase 
complex phosphorylation. Free E2F then transactivates the S-phase gene promoters 
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and proliferates through the cell cycle, resulting in cell cycle dysregulation (Iglesias 
etal., 1998). 
、 It has been suggested that various cellular oncogenes are closely associated with 
cellular proliferation and that its inappropriate expression is involved in 
carcinogensis and in tumour progression of cervical cancers. Activation of these 
oncogenes by structural alterations within the gene sequences, transposition and 
overexpression is associated with neoplastic growth in tumours. Among many 
oncogenes, myc and ras are commonly expressed in cervical cancers (Iwasaka et al., 
1992; Slagle et al., 1998). Amplification and structural alterations of the c-myc 
proto-oncogene have been demonstrated and showed that c-myc overexpression can 
be found in 44% of squamous cell carcinoma of the cervix and in transformed cells 
obtained by HPV 16 and HPV 18 transfection (Couturier et aL, 1991). Recently, 
HPV 16 and HPV 18 E6 oncoproteins have been shown to have additional 
transforming activities independent of p53 (Spitkovsky et al.，1996). The other 
function of these E6 oncoproteins is their ability to transactivate the c-myc promoter. 
Besides, binding of the retinoblastoma protein pRb by HPV 16 and HPV 18 E7 
causes the release Rb-mediated repression of c-myc and the activation of myc gene 
can led to the progression and development of cervical cancers. 
The ras oncogenes, H, K and N-roy, are a family of genes coding for a 
membrane-associated protein, p21, which possesses inherent guanine triphosphatases 
(GTPase) activity. Point mutagenesis at codons 12, 13 and 61 occurs in ras activation 
and results in cellular transformation (Tenti et al., 1995; Dokianakis et al., 1998; 
0'Leary et al., 1998). These ras mutation happens most frequently at codon 61 and a 
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mutation in codon 12 of the H-ros’ oncogene has further been implicated in the 
pathogenesis of cervical cancers. As the mutant ras oncogene can convert HPV-
immortalized keratinocytes to the tumorigenic state, activation of the ras gene is 
、strongly related to advance cervical cancers (Willis et al., 1993). 
Chromosomal abnormalities and alterations in ploidy are regularly detected in 
HPV-associated cervical cancers and HPV-immortalised cell lines (Mullokandov et 
al., 1996; Kim et al., 1997). Cytogenetic analyses of cervical cancers shows some 
non-random alterations of several chromosomes, particularly in chromosome 1, 3, 11 
and 17 (Kersemaekers et al., 1998; Mannion et al., 1998). Chromosome 1 is 
commonly involved in structural and numerical alterations with frequent loss of 
heterozygosity in the short arm at lp36. These changes are found in early 
premalignant cervical lesions. Another common region of loss of heterozygosity is 
on the short arm of chromosome 3 which occurs frequently in both invasive cancers 
and cervical premalignancies, suggesting that like chromosome 1, these alterations 
may play a role in the progression to tumorigenicity (Chu et al., 1998; Maitra et al., 
1999). In addition, functional studies on chromosome 11 revealed that genes present 
on chromosome 11 are capable of suppressing tumorigenicity in cell lines derived 
from cervical cancers, demonstrating that aberration of these gene are related to the 
tumorigenic progression (Bethwaite et al., 1995; Mugica-Van Herckenrode et al., 
1999). For chromosome 17, structural changes in this chromosome result in the loss 
oftumour suppressor gene p53 on 17p. As loss ofheterozygosity frequently detected 
in cervical cancers, it indicates that the tumour suppressor genes play an important 
role in the development of cervical cancers (Southern and Herrington, 1997; 
Huettner et al., 1998). 
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l,3.6Sequence Variation 
Recent studies have shown that most of the intermediate-risk and high-risk 
、HPVs infection did not progress to cervical cancers. Apart from the difference in 
exposure to co-factors, the sequence variation in the two important viral oncogenes 
E6 and E7 may also be relevant. It has been demonstrated that certain variants might 
have a higher oncogenic potential than the others might. Determining the functional 
differences among HPVs variants, and to elucidate their relative risks for progression 
to cervical cancers can be relevant for the design of preventative strategies. Recently, 
the study of HPV variants have been focused on establishing their intertypic and 
intratypic phylogenetic relationships based on nucleotide sequence analysis of HPV 
6, 16 and 18 (Ku et al., 1997; Xi et al., 1997). The identification and characterization 
of the sequence variation within the high-risk HPV types provided a better 
understanding on the association of a particular HPV variant to the development of 
cervical cancers. Extensive studies on the sequence variation within the L1, L2, E2, 
E6 and E7 open reading frames reveal certain sequence-specific changes could alter 
the biological functions of the virus such as the ability to transform cells and thus 
affect its carcinogenic potential. 
HPV E6 variants have shown to be more prevalent in cervical cancers patients. 
Recently, nucleotide change from A to G at position 131 has been reported in many 
studies and such variants have been defined as a subclass of the HPV 16 E lineage 
(HPV 16 E-G 131). Yamada also found an additional A to G nucleotide transition at 
position 350 in the European samples, a T to G nucleotide change at position 178 in 
the Asian samples and four nucleotide changes at positions 145 (T to G), 286 (T to 
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A), 289 (A to G), and 335 (C to T) in all Asian-American, African-1 and African-2 
samples (Yamada et al., 1997). All these variants being found within the E6 region 
seemed to carry differences in oncogenic potential from different geographical 
、regions. 
Several HPV 16 E6 amino acid changes were noted in positions crucial for p53 
interaction at amino acid positions 3, 10, 11 and 78 or for host immune surveillance 
at amino acid positions 3, 11, 14，25, 27, 55, 58, 60, 78 and 83 (Zehbe et al.，1998a). 
He also showed that the risk of developing CJN 2 and CEs[ 3 was not the same within 
HPV 16 E6 variants. An important E6 L83V mutation (leucine to valine) at amino 
acid position 83 was identified and demonstrated that women infect with E6 L83V 
variant would develop CESf 3 inevitably (Alemi et al., 1999). All women with 
cervical cancers under study also carried this variant suggested its strong association 
with the development of cervical cancers (Zehbe et al., 1998b). 
The E7 genes are consistently expressed and retained in cervical cancers cell 
lines and are associated with malignant progression. The E7 open reading frame 
encodes a 98-amino-acid protein, which can bind to the tumour suppressor gene 
product, pRb (Watanabe et al., 1990). The E7 gene consists of three distinct regions, 
each with specific domain for structural and biological functions. The N-terminal 
region of E7 gene at amino acid positions 2 to 43 shows sequence homology to 
adenovirus E lA and simian virus 40 large T antigen and can transactivate the 
adenovirus E2 promoter (Chellappan et al, 1992; Massimi et al., 1996). The C-
terminal region contains two Cys-X-X-Cys motifs, one at amino acid positions 58 to 
61，while the other at 91 to 94. Both of them can bind to zinc and thus stabilise the 
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E7 protein for efficient functioning. It also involves in phosphorylation by casein 
kinase II at serine-31 and serine-32. Sequence variation on HPV types 6，16 and 18 
within the Cys-X-X-Cys motifs and the casein kinase II phosphorylation region are 
、studied most extensively in order to determine the association of mutation in these 
regions to transforming potential (Icenogle et al., 1991; Song et al., 1997). 
In the Cys-X-X-Cys motifs, reduction in transforming activity are observed with 
sequence variation at amino acid positions 58 and 91 (Edmonds and Vousden, 1989). 
HPV 18 E7 cysteine mutants loss its ability for zinc binding. This mutation has no 
change on pRb binding suggests that cysteine mutant can still bind to Rb protein and 
is insufficient for transcription factor E2F dissociation (McIntyre et al., 1993). E7 in 
a dimeric form with intact Cys-X-X-Cys motifs is required for the disruption of Rb-
E2F complex and these motifs, especially at amino acid position 91 to 94, are 
important for the E7 protein to form a stable structure by binding with zinc. 
The degree ofphosphorylation ofE7 at casein kinase II phosphorylation site at 
amino acid positions 30 to 37 by casein kinase II is an important factor in the 
oncogenic potential of HPVs (FirzlafF et al., 1989). Eliminating either of the two 
serines at amino acid position 31 or 32 individually has only little effect on 
phosphorylation. However, double sequence variation at both sites at the same time 
causes a large reduction in its biological activity (Barbosa et al., 1990). Although 
mutation of serines does not affect the ability of E7 to cooperate with ras oncogene 
in cell transforming, phosphorylation might have a minor effect in the oncogenic 
potential of E7 by modulating the interaction of E7 to other cellular proteins 
(Chesters et al., 1990). Substitutions at amino acid positions 28 (leucine to 
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phenylalanine) and 29 (asparagine to serine) also affect phosphorylation which in 
tum alter the transforming properties ofE7 (Fujinaga et al., 1994). As mutations in 
the casein kinase II recognition site have no effect on E7-pRb complex formation, it 
、indicates that casein II phosphorylation site is not essential for Rb binding. It has 
been shown that amino acid changes at positions 5 (threonine to lysine) and 29 
(asparagine to serine) have the similar transforming potential with the prototype and 
these sites are important for transforming activity ofE7. On the other hand, mutation 
at amino acid position 2 (histidine to asparagine) drastically reduces the E7 
transactivating ftmction (Watanabe et al., 1990). However sequence variations being 
found at amino acid positions 47 (proline to leucine) and 76 (arginine to cysteine) are 
found to be insignificant for the biological functions ofE7 (Eschle et al., 1992). 
1.4 Project Design 
This project is divided into three parts. In the first part, three DNA extraction 
methods for paraffin-embedded tissue were compared. Their extraction efficiency for 
human DNA and HPV DNA were accessed by PCRs targeting the house-keeping 
beta-globin gene and the HPV L1 open reading frame respectively. In addition, the 
predictive value of using beta-globin PCR to access the adequacy of HPV DNA 
extraction was also addressed. 
For the second part, the prevalence and genotype distribution of HPV in our 
local population were accessed. The prevalence of HPV infection has been widely 
studied in worldwide with variable results. Still little research has been published 
regarding the prevalence of HPV infection in Chinese women. To elucidate the 
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epidemiology of HPV infection in Chinese population, we sought to determine and 
analysis the genotype-specific prevalence of HPV infection in Chinese women with 
normal cervix, condyloma, cervical intraepithelial lesions and cervical cancers. 
、Understanding the distribution of cancer-associated HPV types has important 
implications for the development of vaccines for the prevention of cervical cancer 
and for HPV DNA based screening assays for cervical cancer. 
For the third part, the sequence variation of HPV 16 E7 oncogene was 
examined. HPV 16 is found to be the most common HPV types in patient with high-
grade cervical lesions and cervical cancers in worldwide case studies. By sequencing 
the HPV 16 E7 region, it is possible to detect genomic variants that are associated 










MATERIALS AND METHODS 
2.1 Evaluation of HPV DNA Extraction Methods for Paraffin-
、 
Embedded Tissues 
2.hl Study Population 
A total of 20 archived paraffin-embedded tissues collected from Chinese 
women with histology-confirmed invasive cervical squamous cell carcinoma during 
the period 1993-1995 were retrieved from the Department of Anatomical and 
Cellular Pathology, The Chinese University ofHong Kong, Prince ofWales Hospital. 
2,L2 Paraffin-Embedded Tissues Collection 
For each paraffin-embedded cervical carcinoma tissue block, four slides of 5-
^m thick were cut in triplicate and transferred into 1.5-ml microfuge tubes. The area 
of cutting was carefully selected to ensure an equal volume of tissue was collected in 
each set. Sections adjacent to the beginnings and endings of cutting were examined 
to guarantee the inclusion of tumour tissue. Particular care, with the use of separate 
knives for cutting each specimen, was taken to avoid cross-contamination between 
specimen blocks. 
ZL3 DNA Extraction 
Three different DNA extraction methods, phenol-chloroform, microwave-based 
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and QIAGEN spin column-based were applied for each case. Phenol-chloroform is a 
classical DNA extraction method that has been used since the 1970s and remains as 
one of the most commonly used methods today. This traditional DNA extraction 
“method for paraffin-embedded tissues makes use of organic solvent in the 
deparafFmising step, followed by phenol-chloroform-isoamyl alcohol treatment for 
DNA purification (Mahony, 1996). The microwave-based extraction is an in-house 
method that does not require the use of organ solvent for deparafFinisation. The 
commercially available QIAGEN spin column is a simple-to-use method for 
extracting DNA. 
2.1.3.1 Phenol-Chloroform Extraction 
The tissues were dewaxed twice by 1 ml of xylene. One milliliter of 100% 
ethanol was added to the pellet to remove residual xylene after each xylene wash. 
After incubation for two hours at 37。C for ethanol evaporation, the tissues were 
resuspended in 300 pl ofdigestion buffer (50 mM Tris, 5 mM EDTA, pH 8; and 300 
pg/ml proteinase K) and incubated overnight at 56。C for proteinase K digestion. For 
DNA purification, a mixture of 300 pl of phenol-chloroform-isoamyl alcohol 
(25:24:1) was added to the digested solution and mixed vigorously until an emulsion 
was formed. After centrifugation for five minutes, the aqueous phase was transferred 
to a new 1.5-ml microfuge tube. These purification steps were repeated twice, 
followed by the addition of 300 pl of chloroform-isoamyl alcohol (24:1) and 
centrifugation for one minute at 4。C. To recover DNA, 75 J^l of sodium acetate (final 
concentration 0.25 M, pH 5.2) and 1 ml of 100% ethanol was added for an overnight 
precipitation at —70。C. After centrifugation for 30 minutes at 4。C, the pellet was 
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washed once with 70% ethanol and spun again for 10 minutes. The pellet was then 
air dried at room temperature and the DNA was eluted in 200 jjl ofBuffer AE. 
、2,1,3.2 Microwave Extraction 
The paraffin-embedded tissues collected in microfuge tubes were digested with 
200 \Ji\ ofdigestion buffer (50 mM Tris-HCL, pH 8.5; 1 mM EDTA and 0.5% Tween 
20) (Banerjee et al., 1995). These tubes were tightly capped and subjected to high 
power microwave irradiation for 1.5 minutes with the total irradiation time being 
split into 15-second segments to prevent spilling of the solution. After centrifugation 
for 10 minutes at room temperature, the supernatant containing the paraffin ring was 
removed, and proteinase K (20 mg/ml) was added to the remaining digestion buffer 
for an overnight digestion at 56°C. After centrifugation for another five minutes, the 
DNA containing supernatant was collected and boiled for 10 minutes at 95。C to 
denature residual proteinase and proteins. 
2,L3.3 QMGENSpin Column Extraction 
DNA was extracted from paraffin-embedded tissues using a commercially 
available system, the QIAamp DNA Mini Kit (QIAGEN, GmbH, Germany). The 
tissues were washed twice with 1200 pl of xylene to deparaffinise the section and 
1200 [}\ of 100% ethanol was added to the pellet to remove residual xylene after each 
xylene wash. The tissues were digested with 180 [}\ of Buffer ATL and 20 J^l of 
proteinase K (20 mg/ml) for overnight at 56。C. After digestion, 200 [}\ ofBuffer AL 
was added and incubated for 10 minutes at 70。C, followed by mixing with 200 pl of 
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100% ethanol. The solution was transferred into the QIAamp spin column and 
centrifuged for one minute. The column was then washed with 500 l^l of Buffer 
AW1, spun for one minute, followed by washing with Buffer AW2 and spun for 
、another three minutes. The DNA adherent to the column was eluted with 200 pl of 
Buffer AE at room temperature and centrifuged for one minute. 
2.1.4 PCR Amplification 
Four sets ofPCR were used to assess the quality of extracted preparations. The 
first two sets, PC03/^C07 (De Roda Husman et al., 1995a) and Beta-GPl/Beta-GP2 
(Lo et al., 1989) target the housekeeping beta-globin gene. The other sets, 
MY09MY11 (Manos et al., 1989) and GP5+/GP6+ (De Roda Husman et al., 1995b) 
were used for amplifying HPV DNA from the L1 open reading frame. The 
PC03/PC07 primer set served to assess HPV DNA quality with fragment of 509-bp 
or longer, that could be further used for HPV detection by using MY09MY11. The 
other beta-globin primer set, Beta-GPl/Beta-GP2 was used to assess HPV DNA 
quality with fragment of 355-bp or longer, that could be further used for HPV 
detection by using GP5+/GP6+ 
2.1.4.1. PCR Amplification forHuman Beta-globin Gene 
The DNA extracted from paraffin-embedded tissues was used for amplification 
of human beta-globin gene, using primer combinations PC03/PC07 and Beta-
GPl/Beta-GP2 to generate the 509-bp and 355-bp products respectively (Table 1). 
29 
2.1.4.2 PCR Amplificationfor HPVDNA 
HPV DNA was detected by PCR using two consensus primer sets: the 
^ degenerated MY09MY11 and the general primer-mediated GP5+/GP6+. These 
consensus primers target the highly conserved HPV L1 open reading frame ofat least 
40 genital HPV types (Bernard et al., 1994), generating the 450-bp and 150-bp DNA 
fragments respectively (Table 2). 
21.5 Optimisation of PCRs 
2,L5,1 Optimisation of Beta-globin PCRs 
Beta-globin PCRs were optimized by trying different annealing temperatures, 
using serial dilution of known concentration of 1X10^ white blood cells per five 
microlitres inoculum. Annealing temperatures at 53°C, 55°C and 57°C were used 
respectively in each PCR reaction. After optimising the annealing condition, primer 
concentrations ranging from 0.125 pM, 0.25 pM, 0.5 \}M and 1 pM were compared 
to determine the optimal primer concentration for each assay. PCRs were performed 
in a 50-pl reaction volume for 40 cycles with a reaction mix containing 10 mM Tris-
HC1 (pH 9.0), 50 mM KC1, 1.5 mM MgCl2, 200 pM of each dNTP and 1.5 units of 
Taq polymerase (Pharmacia Biotech, Sweden). The PCR cycling conditions included 
an initial denaturation at 94°C for four minutes, followed by 40 cycles of one minute 
denaturation at 94°C, one minute annealing and 1.5 minutes extension at 72°C. An 
additional primer extension was carried out at 72°C for eight minutes. 
30 
1L5.2 Optimisation ofHPVPCRs 
The PCRs were performed on serial dilutions of recombinant plasmids 
^ containing full length ofHPV 16 (pHPV 16) genome mixed with 1 ng/pl of salmon 
sperm DNA. All PCR reagents were keep constant except for the annealing 
temperature and the primer concentration. PCRs with annealing temperatures at 
53。C, 55。C and 57。C were tried for the degenerated MY09MY11 PCR, while 
annealing temperatures at 43°C, 45°C and 47。C were tried for the general 
GP5+/GP6+ PCR. After optimising the annealing condition for MY09MY11 and 
GP5+/GP6+ PCRs, primer concentrations ranging from 0.125 [M, 0.25 [JM, 0.5 [M 
and 1 \JM were compared to determine the optimal primer concentration for each 
assay. PCRs were performed in a 50-pl reaction mixture containing 10 mM Tris-HCl 
(pH 9.0), 50 mM KC1, 1.5 mM MgCl2, 200 ^JM of each dNTP and 1.5 units of Taq 
polymerase (Pharmacia Biotech, Sweden). The PCR cycling conditions were initial 
denaturation at 94。C for four minutes, followed by 40 cycles of one minute 
denaturation at 94°C, one minute annealing and 1.5 minutes extension at 72°C. An 
additional primer extension was carried out at 72°C for eight minutes. 
2. L 5.3 Analytical Sensitivity of PCRs 
The analytical sensitivity of each PCR was determined by performing PCR 
using known concentration of white blood cell lysate or pHPV 16 with the optimised 
annealing temperatures and primer concentrations. 
2,1.5.3,1 Analytical Sensitivity of Beta-globin PCRs 
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Analytical sensitivity of the beta-globin PCRs was performed on various 
concentrations of white blood cell lysate, which contained 10^  to 10^  white blood 
、cells per five microlitres of inoculum. Optimised conditions of primer concentration 
at 0.25 [JM and annealing temperature at 57。C were used for PC03/PC07 and Beta-
GPly^eta-GP2 PCRs and were carried out in a 50-pl reaction volume with an initial 
denaturation at 94°C for four minutes, followed by 40 cycles of one minute 
denaturation at 94°C, one minute annealing at 57T and 1.5 minutes extension at 
72°C. An additional primer extension was carried out at 72。C for eight minutes. 
Zl.5.3.2. Analytical Sensitivity of HPVPCRs 
To defme the analytical sensitivity of the HPV PCRs, various concentrations of 
pHPV 16, which contained 10。to 10^  copies of HPV 16 per five microlitres of 
inoculum in a background of 1 ng/pl of salmon sperm DNA were subjected to PCRs 
with the optimised primer concentration at 0.25 pM of each primer set. Optimised 
annealing temperatures at 55。C (MY09MY11 PCR) and 45。C (GP5+/GP6+ PCR) 
were performed in a 50-pl reaction volume with an initial denaturation at 94°C for 
four minutes, followed by 40 cycles of one minute denaturation at 94°C, one minute 
annealing at 55°C or 45°C and 1.5 minutes extension at 72°C. An additional primer 
extension was carried out at 72。C for eight minutes. 
ZL5,4 Detection ofPCR Products 
Ten microlitres of the PCR products were analysed on 2% agarose gel by 
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electrophoresis with ethidium bromide staining. The marker used was HaelW ¢174. 
2.1.6 PCR Evaluation ofDNA Extraction Methods 
、 
21,6.1 Beta-globin PCRs 
PCRs were carried out for the 20 paraffin-embedded tissue samples in a 50-pl 
reaction mixture containing 10 mM Tris-HCl (pH 9.0), 50 mM KC1, 1.5 mM MgCl2, 
200 [JM of each dNTP, 0.125 [M of each primer and 1.5 units of Taq polymerase 
(Pharmacia Biotech, Sweden). The PCRs were performed with an initial denaturation 
at 94。C for four minutes, followed by 40 cycles of one minute denaturation at 94。C, 
one minute annealing at 57°C and 1.5 minutes extension at 72°C. An additional 
primer extension was carried out at 72。C for eight minutes. Distilled water was used 
as negative controls. DNA from white blood cells was used as the positive controls. 
2,L6,2HPVPCRs 
2.L6.Z1 MY09MY11 PCR 
For all the 20 paraffin-embedded tissue samples, PCR was carried out in a 50-
Ml reaction mixture containing 10 mM Tris-HCl (pH 9.0), 50 mM KC1, 1.5 mM 
MgCl2, 200 [M of each dNTP, 0.25 pM of each primer and 1.5 units of Taq 
polymerase (Pharmacia Biotech, Sweden). The thermal cycling conditions were: (a) 
an initial denaturation at 94。C for four minutes; (b) 40 cycles of one minute 
denaturation at 94°C, one minute annealing at 55°C and 1.5 minutes extension at 
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72。C; and (c) an additional primer extension at 72。C for eight minutes. A negative 
control using distilled water was added following every fifth specimen, and two 
positive controls consisting approximately 1000 and 100 copies of pHPV 16 were 
"included. 
ZL6,2,2 GP5+/GP6+PCR 
For all the 20 paraffin-embedded tissue samples, GP5+/GP6+ PCR was 
performed on a 50-pl reaction mixture containing 10 mM Tris-HCl (pH 9.0), 50mM 
KC1, 1.5 mM MgCl2,200 pM ofeach dNTP, 0.25 [M of each primer and 1.5 units of 
Taq polymerase (Pharmacia Biotech, Sweden). The thermal cycling conditions were: 
(a) an initial denaturation at 94。C for four minutes; (b) 40 cycles of one minute 
denaturation at 94°C, one minute annealing at 45°C and 1.5 minutes extension at 
72。C; and (c) an additional primer extension at 72。C for eight minutes. A negative 
control using distilled water was added following every fifth specimen, and two 
positive controls consisting approximately 1000 and 100 copies of pHPV 16 were 
included. 
2.1.6J Detection ofPCR Products 
Ten microlitres of the PCR products were analysed on 2% agarose gel by 
electrophoresis with ethidium bromide staining. The marker used was HaeWl ¢174. 
The intensity of the beta-globin amplicons was graded to 1+, 2+ and 3+ according to 
ethidium bromide staining intensity. 
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2.2 Prevalence and Genotype Distribution of HPV 
2,2,1 Study Populations 
、 
2.2AA Women with Normal Cervices 
Cervical scrapes were collected from Chinese women who participated in 
cervical screening at the Shatin Community Cervical Screening Clinic, Prince of 
Wales Hospital from May of 1995 to September of 1998. At gynecological 
examination, cervical smears were taken for cervical cytologic diagnosis as well as 
for HPV DNA testing. The cervical cytology results at their first visit and the 12-
month follow up visit were retrieved. Women who had normal cervical cytology 
results at both visit were selected. As a result, 593 Chinese women were included 
and their cervical samples collected during their first visit were examined. 
2,2,1.2 Women with Abnormal Cervical Cytologies 
The study population included consecutive Chinese women referred to the 
colposcopy clinic at Queen Elizabeth Hospital between August of 1996 to September 
of 1998, because of abnormal pap smears detected by public or private primary 
screening centers. Patients who are pregnant or with a previous history of histology-
confirmed cervical premalignant or malignant were excluded. A total of 440 women 
were included and their cervical scrapes were examined. 
2,2,1.3. Women with Cervical Cancer 
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The 20 archived paraffin-embedded tissues collected from Chinese women with 
histology-confirmed invasive squamous cell carcinoma that had been used for the 
^evaluation ofHPV DNA extraction methods were also included into this part for the 
assessment ofHPV genotype prevalence and distribution. 
2,2,2 Disease Classification 
All cytology smears were assessed by pathologists or cytotechnicians and 
classified according to the Bethesda system (Lundberg, 1988) for reporting cervical 
cytologic diagnosis. Under this system, all cytologic abnormalities were classified as 
either low-grade or high-grade squamous intraepithelial lesions. Low-grade 
squamous intraepithelial lesions included normal cells with koilocytosis as well as 
mild dysplasia whereas high-grade squamous intraepithelial lesions ranging from 
moderate to severe dysplasia together with carcinoma in situ. Atypical squamous 
cells ofuncertain significance was used for smears contained atypical cells that could 
not be classified. 
Histological diagnosis was performed on biopsies, grading cervical 
intraepithelial lesions into CW 1, CW 2, CW 3 and invasive carcinoma (Scully et 
al., 1994). 
2.2,3 Specimen Collection and Preparation 
2,2,3,1 Cervical Scrape Collection 
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Cervical exfoliated cells from women with normal and abnormal cervical 
cytologies were collected by cervix brush or a modified Ayre spatula, which was then 
、agitated in 10 ml of phosphate-buffered saline. Cells were pelleted by centrifugation 
for 10 minutes at 3000 rpm and resuspended in one millilitre of phosphate-buffered 
saline, stored at -70°C until further analysis. 
1Z3.L1 DNA Extraction 
Cells were lysed with 50 i^l of digestion solution (39 i^l of 50 mmol/1 Tris-HCl 
pH 9.5], 1 mmol/1 EDTA; 10 i^l ofTween 20; and one microlitre of proteinase K [20 
mgy^ ml]) in a total reaction volume of 100 jil of cellular suspension and incubated for 
one hour at 55°C (Ehrlich and Greenberg, 1994). The solution was then heated for 10 
minutes at 95°C for inactivation of protease. Five microlitres of the supernatant were 
used for HPV detection. 
2.14HPVDNA Detection 
PCR amplification ofHPV DNA on cervical scrapes was performed using the 
consensus degenerated primers MY09MY11 and the general primers GP5+/GP6+ 
that can detect at least 40 genital HPVs (Manos et al., 1989) (Tables 3a, 3b, 4a and 
4b). 
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Z2.4A MY09MY11 PCR 
PCR was carried out in a 50-pl reaction mixture containing 10 mM Tris-HCl 
、(pH 9.0), 50 mM KC1, 1.5 mM MgCl2, 200 [JiM of each dNTP, 0.25 ^lM of each 
primer and 1.5 units of Taq polymerase (Pharmacia Biotech, Sweden). The thermal 
cycling conditions were: (a) an initial denaturation at 94°C for four minutes; (b) 40 
cycles of one minute denaturation at 94°C, one minute annealing at 55°C and 1.5 
minutes extension at 72°C; and (c) an additional primer extension at 72。C for eight 
minutes. A negative control using distilled water was added following every fifth 
specimen, and two positive controls consisting approximately 1000 and 100 copies 
of pHPV 16 were included. 
Z2.4.2 GP5+/GP6+PCR 
GP5+/GP6+ PCR was performed in a 50-[jl reaction mixture containing 10 mM 
Tris-HCl (pH 9.0), 50 mM KC1, 1.5 mM MgCb, 200 pM of each dNTP, 0.25 \M of 
each primer and 1.5 units of Taq polymerase (Pharmacia Biotech, Sweden). The 
thermal cycling conditions were: (a) an initial denaturation at 94。C for four minutes; 
(b) 40 cycles of one minute denaturation at 94。C, one minute annealing at 45。C and 
1.5 minutes extension at 72。C; and (c) an additional primer extension at 72°C for 
eight minutes. A negative control using distilled water was added following every 
fifth specimen, and two positive controls consisting approximately 1000 and 100 
copies of pHPV 16 were included. 
ZZ4J Detection ofPCR Products 
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A total of 10 pl of each ofthe PCR products was analyzed by 2% agarose gel 
electrophoresis and stained with ethidium bromide to detect the genital HPVs. The 
marker used was HaeMl c|)174. 
、 
2 2 5 HPV Genotyping 
The genotypes of HPVs were identified by restriction fragment length 
polymorphisms based on a previously published approach. This approach has been 
used successfully to identify more than 40 genital HPVs (Bernard et al., 1994) (Table 
5). Standard plasmids of pHPV 6, 11, 16 and 18 were used to verify the restriction 
patterns after MY09MY11 PCR from the L1 open reading frame. Five microlitres of 
the PCR products were digested with two restriction endonucleases, Rsa I and Dde I 
(0.1 unit/pl) (Boehringer Mannheim, GmbH, Germany) separately in a lO-pl reaction 
mixture containing digestion buffer. The digestion was allowed to proceed overnight 
at 37°C and terminated by heating at 95°C for one minute. Digested fragments were 
electrophoresed on a 3% agarose gel (MetaPhor™ Agarose, FMC Bioproducts, 
Denmark) with 25-bp DNA Step Ladder (Promega, Madison) as marker for fragment 
size assessment. 
2.3 Sequence Variation ofHPV 16 E7 Gene 
2,3,1 Study Population 
Using the MY09MY11 PCR for HPV detection and genotyping by restriction 
fragment length polymorphisms, 48 isolates of HPV 16 were identified. In order to 
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detect more HPV 16 isolates for sequencing variation analysis, PCR was performed 
on another 77 cervical scrapes using type-specific primers targeting the HPV 16 E7 
region. As a result, 44 more HPV 16 were detected. Finally a total of 92 isolates of 
、HPV 16 were included. These included nine normal cervical scrapes, 10 CJN 1, 14 
CJN 2, 46 CJN 3 and 11 squamous cell carcinoma and two adenocarcinoma. To 
efficiently determine variants ofHPV 16 in the E7 region, PCR-directed sequencing 
was used and a 297-bp fragment corresponding to HPV 16 E7 region, nucleotide 
position 562 to 858, was chosen for analysis. 
2.3.2 Optimisation ofHPV16 E7Nested PCR 
Primer sets specific for the HPV 16 E7 encoding region were designed base on 
the reference strain of HPV 16 available in the GeneBank (Accession number: 
K02718). By using the Primer software (Primer designer version 2.0), type-specific 
oligonucletoide primer sets E7-l/E7-2 and E7-3/E7-4 specific for HPV 16 E7 region 
were designed. These primer sets were checked against all HPV types using the Blast 
search and were shown to bind specifically with HPV 16 E7 open reading frame only 
(Table 6). 
Optimisation of the HPV 16 E7 PCR was performed using serial dilutions of 
recombinant plasmids containing full length of HPV 16 genome. All PCR reagents 
were keep constant except for the annealing temperature and the primer 
concentration. PCRs with annealing temperatures at 53T, 55°C and 57T were 
compared first, followed by comparing primer concentrations ranging from 0.125 
[M, 0.25 [JM, 0.5 ^JM and 1 [M to determine the optimal primer concentration for 
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each assay. PCRs were performed in a 30-pl reaction mixture containing 2 mM Tris-
HCL (pH8.0), 10 mM KC1, 1.5 mM MgCb, 200 [}M ofeach dNTP, one unit ofBio-
X-Act™ Taq polymerase (Bioline, U.S.A.). The PCR cycling conditions included an 
、initial denaturation at 94。C for four minutes, followed by 30 cycles of one minute 
denaturation at 94°C, one minute annealing and 1.5 minutes extension at 72°C. An 
additional primer extension was carried out at 72°C for eight minutes. 
Z3J HPV16 E7 Nested PCR 
Nested PCR amplification of a 572-bp fragment for outer PCR and a 368-bp 
fragment for inner PCR ofHPV 16 E7 gene were performed. The first PCR reaction 
mixture contained 2 mM Tris-HCL (pH8.0), 10 mM KC1, 1.5 mM MgCl2, 200 jjM of 
each dNTP, 0.25 pM of each outer primer, one unit of Bio-X-Act™ Taq polymerase 
(Bioline, U.S.A.) and three microlitres of template DNA. The Bio-X-Act™ Taq 
polymerase was used as it possesses a 3, to 5’ proof-reading activity which prevent 
misincorporations during nucleotide extension. The amplification conditions were an 
initial denaturation at 94°C for four minutes, followed by 30 cycles of one minute 
denaturation at 94。C, one minute annealing at 57。C and 1.5 minutes extension at 
72°C. To ensure complete extension of the amplified DNA, the final extension step 
was prolonged for another eight minutes. Conditions for the second round of PCR 
were the same, with the use ofprimer pair E7-3/E7-4 at 0.25 \}M and two microlitres 
ofthe first PCR product as template DNA. The cycling conditions used were also the 
same except the annealing and extension step in which 45 seconds at 57°C and one 
minute at 72°C were used respectively. A negative control using distilled water was 
added following every fifth specimen. 
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2,3.3,1 Detection of PCR Products 
、 Five microlitres of the PCR products were analyzed by electrophoresis in 2% 
agarose gel with ethidium bromide staining. The marker used was HaelW ¢174. 
Z3,4Purification ofNestedPCR Products 
PCR products were purified by MicroSpin™ S-400 HR Columns (Amersham 
Pharmacia, U.S.A.). After resuspending the resin in the column by vortexing, the 
bottom ofthe closure was removed and the cap was loosen with one-fourth turn. The 
column was pre-spin at 3000 rpm for one minute and the flow-through was 
discarded. After adding the PCR products to the top-center of the resin, the column 
was again centrifiiged for another two minutes and the purified products were 
collected into a 1.5-ml microftige tube. After purification, the amount of the PCR 
products was assessed by agarose gel electrophoresis and ethidium bromide staining. 
2.3.5Dh^ect Cycle Sequencing 
2,3,5,1 Cycle Sequencing Reaction 
Cycle sequencing was performed using the ABI Prism® BigDye™ Terminator 
cycle sequencing ready reaction kit (Perkin-Elmer Cetus, U.S.A.). Each sample was 
sequenced in the forward direction using E7-3 inner primer as the sequencing primer. 
The sequencing reaction mix contained four microlitres of the terminator ready 
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reaction mix (Tris-HCl buffer [pH9.0]; MgCb ； A,G,C and T-Dye terminators; 
deoxynucleotide triphosphates [dATP, dCTP, dITP, dUTP] and AmpliTaq DNA 
polymerase), one microlitre of sequencing primer (1.5 pmol/ p l ) and five microlitres 
、of template DNA (3-10 ng). Reaction was performed for 25 cycles of 10 seconds 
denaturation at 96。C, five seconds annealing at 50。C and four minutes extension at 
60°C. 
2,3,5,2 Purification of Cycle Sequencing Products 
Using a Centri-Sep™ spin column (Princeton Separations, NJ), amplified cycle 
sequencing products were purified from contaminated primers, dye-terminators and 
dNTPs. The column was hydrated with 800 ml of distilled water for two hours at 
room temperature. With the removal of the top and bottom caps, the column was 
allowed to drain completely by gravity and the flow-through was discarded. After 
centrifugation for two minutes at 750 X g to further remove interstitial fluid, the 
amplified cycle sequencing products were added directly onto the center of the gel 
bed at the top of the column. The column was spun again for another two minutes 
and the purified products were collected into 1.5-ml microfuge tubes. 
2.3,5.3 Electrophoresis on DNA Sequencer 
Ten microlitres of the purified cycle sequencing products were resuspended in 
six microlitres of Template Suppression reagent. The solution was heated for two 
minutes at 95°C and chill on ice immediately. By using a short capillary, the sample 
was injected into the ABI Prism 310 DNA sequencer for sequence analysis. 
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2.3.6 Data Analysis 
、 All DNA and predicted amino-acid sequences were compared to the prototype 
HPV 16 sequence available in the GeneBank (Accession number: K02718), using the 
SBVIONIC software to identify any sequence variation in the HPV 16 E7 region. To 
confirm the mutations detected, three samples were randomly selected from each 
variant group and subjected to repeat PCR and subsequent sequencing using the E7-4 
reverse sequencing primer. 
2.4 Statistical Methods 
Statistical Package for Social Sciences 9.0 software program for Windows 
(SPSS inc., Chicago, 111.) was used for all statistical analysis. Chi square test, 
Fisher's exact test and t-test were used to determine which of the study variables 
played more significant roles than the others in HPV genotype prevalence and 
sequence variation studies. The independent t-test was used to compare age 
distribution among different groups. All statistically analysis were two-tailed. P-
value ofless than 0.05 were regarded as statistically significant. 
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、 3.1 Evaluation of HPV DNA Extraction Methods for Paraffin-
Embedded Tissues 
3AA Optimised Conditions for Beta-globin PCRs 
The optimal annealing temperatures and primer concentrations for PC03yTPC07 
PCR are shown in Figures 1 and 2 whereas for Beta-GPl/Beta-GP2 PCR, the optimal 
annealing temperatures and primer concentrations are shown in Figures 3 and 4 
respectively. 
For PC03/PC07 PCR, by using a high annealing temperature at 57°C and 
3 
primer concentration at 0.25 mM, it showed a detection limit of 10 cells/5- i^l 
inoculum of white blood cell lysate with minimal primer dimer formation and 
background amplification. 
For Beta-GPl/Beta-GP2, using annealing temperature at 5TC and primer 
concentration at 0.25 mM gave the best sensitivity of 10^  cells/5- i^l inoculum of 
white blood cell lysate and with minimal primer dimer formation and background 
amplification. 
As a result, the optimised annealing temperatures and primer concentrations for 
PC03/PC07 and Beta-GPl/Beta-GP2 PCR sets were both at 57。C and 0.25mM to 
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achieve the highest sensitivity with minimal primer dimer formation and background 
amplification. 
、3.L2 Optimised Conditions forHPVPCRs 
The optimal annealing temperatures and primer concentrations for 
MY09MY11 PCR are shown in Figures 5 and 6 whereas for GP5+/GP6+ PCR, the 
optimal annealing temperatures and primer concentrations are shown in Figures 7 
and 8 respectively. 
For MY09MY11 PCR, by using an annealing temperature at 55°C and primer 
concentration at 0.25 mM, it showed the best sensitivity with a detection limit of 100 
copies of HPV 16 genomes and with minimal primer dimer formation and 
background amplification of salmon sperm DNA. 
For GP5+/GP6+, using annealing temperature at 45°C and primer 
concentration at 0.25 mM, it gave the highest sensitivity with a detection limit of 
1000 copies of HPV 16 genomes and with minimal primer dimer formation and 
background amplification. 
In conclusion, the optimised annealing temperatures and primer concentrations 
for MY09MY11 and GP5+/GP6+ PCRs were at 55°C and 45°C respectively and 
both at 0.25 mM to achieve the highest sensitivity with an acceptable level of primer 
dimmer formation and background amplification. 
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3,L3 Analytical Sensitivity of Beta-globin and HPVPCRs 
For the PC03A^C07 and Beta-GPl/Beta-GP2 PCRs, the analytical sensitivity of 
、both sets using annealing temperature at 57°C and primer concentration at 0.25 mM 
were 10^  white blood cells per five microlitres of template inoculum. 
Using MY09/MY11 and GP5+/GP6+ PCR systems with annealing temperatures 
at 55°C and 45°C and primer concentration at 0.25 mM, the detection limit of pHPV 
16 DNAs were 100 and 1000 copies of HPV 16 genomes respectively per five 
microlitres of template inoculum. 
3.1.4PCR Evaluation ofDNA Extraction Methods 
3.L4A PC03/PC07PCRs 
For PC03/PC07 PCR amplification on cervical biopsies, among each extraction 
method, the positive rates for PC03/PC07 PCR were similar with difference in 
amplicon intensity (Figure 9). For the phenol-chloroform extraction method, 10 out 
of 20 (50%) cervical samples were positive with four amplicons gave relatively 
strong bands of intensity grade >2+ (Table 7). With the microwave-based method, 12 
out of 20 (60%) extracts showed positive results with eight of them showed strong 
bands of intensity grade >2+. For the QIAGEN spin column system, 10 out of 20 
(50%) cervical biopsies were positive for PC03/PC07 amplification, in which five of 
them revealed relatively strong band of intensity grade >2+. 
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3.L4,2 Beta-GPl/Beta-GP2 PCRs 
All the samples previously positive for PC03y^C07 PCR (509-bp) (Figure 10) 
、were positive in the Beta-GPl/Beta-GP2 PCR. The extracted preparations were 
subjected to PCR with primers yielding a 355-bp fragment (Figure 11). The overall 
positive rates and amplicon intensity were similar among the three extraction 
methods. Using the phenol-chloroform extraction method, 18 out of 20 (90%) 
extracts were beta-globin positive with 15 amplicons gave a strong bands of intensity 
grade > 2+. With the microwave-based method, 19 out of 20 (95%) extracts showed 
positive beta-globin amplification with 16 of them revealed strong bands of intensity 
grade > 2+. For the QIAGEN spin column method, 19 out of 20 (95%) extracts were 
positive for beta-globin amplification with 16 of them showed strong bands of 
intensity grade > 2+ 
3,L4.3HPVPCRs 
The extracted DNA from the cervical biopsies were ftirther subjected to HPV 
L1 PCR amplification to assess the reliability of using beta-globin amplification as 
an indicator for successful HPV DNA detection. 
QIAGEN spin column method provided the highest positive rate of 90% for 
both HPV PCRs, followed by microwave method with positive rate of 67% in 
MY09MYl lPCR and 83% in GP5+/GP6+ PCR Phenol-chloroform method was the 
most inferior with only 20% yielding the 450-bp fragment of HPV DNA in the 
MY09MY11 PCR and 50% in GP5+/GP6+ PCR (Table 8). When the data were 
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further analysed with respect to the reliability of using beta-globin amplification as 
an indicator for successful extraction of the expected length of target HPV DNA, the 
QIAGEN spin column extraction showed the highest positive predictive value with 
、nine out of 10 (90%) ofthe 509-bp beta-globin positive samples yielding an expected 
size ofHPV DNA. 
For the 28 beta-globin negative samples, HPV DNA can be detected in 24 
(86%) of them. For the phenol-chloroform extraction method, it also produced a 
shorter DNA fragments as HPV DNA was detected in eight samples using the 
GP5+/GP6+ primer set yielding a 150-bp short product fragment. 
3.2 Prevalence and Genotype Distribution of HPV 
3.2.1. HPVDetection 
MY09MY11 and GP5+/GP6+ PCRs, amplifying the highly conserved L1 
region ofthe mucosotropic HPV types were used to detected HPV present in cervical 
scrapes and cervical biopsies. The expected amplicon size o fMY09MY l l PCR was 
450-bp (Figures 12, 13 and 14). The expected amplicon size of GP5+/6+ was 150-bp 
(Figure 15). 
3.Z2HPVTyping 
The restriction fragment length patterns of various representative HPV 
genotypes are shown in Figures 16, 17 and 18. 
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3.2.3 Women with Normal Cervices 
、 The 593 studied Chinese women, who had normal cytology results at 12 
months apart, were aged from 18 to 68 years (mean 42.9; SD 7.6). 
The overall HPV detection rate in this group was 4.2% (25 out of 593). 
Multiple HPV infections, containing two HPV types, were detected in 3 (12%) ofthe 
25 HPV-positive cervical samples. The uncharacterized HPV types was detected in 
1%, followed by HPV 52 (0.8%), HPV 16 (0.7%), HPV 53 (0.5%), HPV 58, HPV 
59, HPV CP141 and HPV CP8304 (0.3% each). The distribution of HPV types is 
shown in Table 9. When women with HPV infections were compared with those 
without any HPV, there was no statistically significant difference in age distribution 
(mean age: 42.68 vs 42.94, P = 0.868, 95% confidence interval: -3.33 to 2.81 by t-
test). 
3.2.4 Women with Abnormal Cervical Cytologies 
A total of440 Chinese women aged from 13 to 86 years (mean 40.6; SD 9.9) 
were studied. Ninety-seven women (22.0%) had normal or inflamed cervices, 113 
women (25.7%) with condyloma, 42 (9.5%) had biopsy-proven CJN 1，60 (13.6%) 
had biopsy-proven O N 2, 104 (23.6%) had biopsy-proven CJN 3 and 24 (5.5%) had 
cervical carcinoma (two patients with invasive adenocarcinoma, others were invasive 
squamous cell carcinoma). When women with HPV infections were compared with 
those without HPV, there was no statistically significant difference in their age 
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distribution (mean age: 39.90 vs 41.23, P = 0.163, 95% confidence interval: -3.18 to 
0.54 by t-test). 
、 HPV type was identified in 199 of the 440 women (45.2%) with abnormal 
cervical cytologies (Table 10) with positive rates of 15.5% in normal or inflamed 
cervix, 28.3% in condyloma, 61.9% in CESf 1, 61.6% in CW 2, 69.2% in CESf 3 and 
70.8% in cervical carcinoma. For HPV typing, HPV 16 (15.2%) was the most 
frequently detected HPV type. The other commonly identified HPV types were 
uncharacterized HPVs (8.4%), followed by HPV 58 (6.6%), HPV 18 (3.0%), HPV 
52 (2.7%), HPV31 (2.5%) and HPV 33 (2.0%). 
The overall HPV-positive infection showed a statistically significant increase in 
risk for high-grade cervical lesions (x^=62.94, P < 0.001 by %^  test; odds ratio: 4.98, 
95% confidence interval: 3.25-7.66). In women with high-grade cervical lesions, 
HPV 16 and HPV 58 were the most frequently detected HPV types, whereas the 
uncharacterized HPV types were commonly identified in women with normal or 
inflamed cervices. When women with low-grade cervical lesions (normal or inflamed 
cervices, condyloma and CJN 1) were compared with those with high-grade cervical 
lesions (CW 2, CJN 3 and cervical carcinoma), the presence ofHPV 16, HPV 33 and 
HPV 58 infection showed a statistically significant increase in risk for high-grade 
cervical lesions {%^  = 62.07, odds ratio: 12.05, 95% confidence interval: 5.55 to 
26.99, P < 0.001 by x^ test for HPV 16; j = 4.61, odds ratio: 4.83, 95% confidence 
interval: 0.91 to 34.07, P < 0.05 by Fisher's exact test for HPV 33; x^ 二 11.18, odds 
ratio: 3.84, 95% confidence interval: 1.57 to 9.67, P 0.001 by f test for HPV 58) 
(Table 11). No significant risk for high-grade cervical lesions was observed for HPV 
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types 11, 18, 31, 39 and 52 and women infected with uncharacterized HPV types also 
showed no significant difference in risk for high-grade cervical lesions (odds ratio: 
0.91, 95% confidence interval: 0.43-1.89). 
、 
The distribution ofHPV risk groups (low-risk, intermediate-risk and high-risk) 
according to the severity of cervical lesions is shown in Table 12. A trend of increase 
in positivity for high-risk group (HPV types 16 and 18) with increase in severity of 
cervical lesion was observed. In contrast, a trend of decrease in positivity ofthe low-
risk group (HPV types 6b and 11) with increase in severity of cervical lesion was 
found. However no significant changes in positivity of the intermediate-risk group 
(HPV types 52 and 58) was observed. 
Among this group of women who had abnormal cytology results, the detection 
of HPV 16 in cervical scrape carried a sensitivity, specificity, positive predictive 
value, negative predictive value of30.9%, 96.4%, 86.6% and 65.2% respectively for 
high-grade cervical lesions. The corresponding sensitivity, specificity, positive 
predictive value, negative predictive value for other eight HPV types are shown in 
Table 13. 
3.2,5 Women with Cervical Cancer 
A total of 20 Chinese women with cervical cancers were aged from 27 to 80 
years (mean 50.4; SD 16.7). Sixteen (80%) had squamous cell carcinoma whereas 
four (20%) were with adenocarcinoma. 
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The overall HPV detection rate was 60% (12 out of 20) (Table 14). HPV 16 
was found to be the most predominant type (40%), followed by HPV 58 (10%). The 
genotype of two positive samples could not be confidently identified as the PCR 
、amplificon intensity was too low. 
3.3 Sequence Variation ofHPV 16 E7 Gene 
3,3,1 Optimised Conditionsfor HPV16 E7 Nested PCR 
The optimal annealing temperatures and primer concentrations for the type-
specific HPV 16 E7 outer primer set (E7-l/E7-2) and inner primer set (E7-3/E7-4) 
are shown in Figures 19, 20, 21 and 22 respectively. 
For outer E7-l/E7-2 PCR, by using annealing temperature at 57°C and primer 
concentration at 0.25 mM, it showed the best sensitivity with a detection limit of 100 
copies ofHPV 16 genomes and with minimal primer dimer formation. 
For inner E7-3y^7-4 PCR, using annealing temperature at 57°C and primer 
concentration at 0.25 mM, it gave the highest sensitivity of 100 copies of HPV 16 
genomes and with less primer dimer formation. 
In conclusion, the optimised annealing temperatures and primer concentrations 
for HPV 16 outer and inner PCR sets were both at 57°C and 0.25mM to achieve the 
highest sensitivity with an acceptable level of primer dimer formation and 
background amplification. 
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J.J.2 HPV16 E7 Sequencing 
、 A total of 125 HPV 16-positive samples were subjected to E7 sequencing. The 
samples known to be HPV 16 positive were re-amplified using HPV 16 E7 nested 
PCR. After purification, 92 out of 125 samples showed amplicon intensity strong 
enough for HPV 16 E7 sequencing (Figure 23). The origin of these 92 samples were, 
nine (9.8%) from patients with normal cytology, 10 (10.9%) with CEsf 1, 14 (15.2%) 
with CE^ 2, 46 (50.0%) with CIN 3 and 13 (14.1%) with cervical cancer. 
3.3J HPV16 E7 Variants 
When compared with the HPV 16 prototype sequence (GeneBank Accession 
number: K02718), seven HPV 16 E7 variants were identified. The first variant, 
designated as "prototype-like" were found in 27 samples (29.3%). The remaining six 
HPV 16 E7 variants were designated as "HPV 16 E7 HK-1" (1.1%), "HPV 16 E7 
HK-2" (3.3%), "HPV 16 E7 HK-3" (60.9%), "HPV 16 E7 HK-4" (3.3%), "HPV 16 
E7 HK-5" (1.1%) and "HPV 16 E7 HK-6" (1.1%) accordingly. 
The prototype-like variant showed 10 silent mutations. In this kind of mutation, 
a substitution of a single nucleotide base will not result in any change in the amino 
acid being encoded. The nucleotide changes were at: nucleotide positions 733, 761, 
790, 845 and 847 with a common base change from T to C, nucleotide positions 664 
and 667 with base change from G to A, nucleotide positions 796 and 831 with base 
change from T to G and nucleotide position 823 with base change from A to G. 
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The other six HPV 16 E7 variants showed nucleotide transitions as well as 
amino acid substitutions (Figure 24). "HPV 16 E7 HK-1" showed mutation at 
、nucleotide position 646 with a base change from A to C, resulting from amino acid 
change at position 28 (leucine to phenylalanine). For "HPV 16 E7 HK-2", it had a 
mutation at nucleotide position 647 with a base change from A to C, resulting from 
amino acid change at position 29 (asparagine to histidine). "HPV 16 E7 HK-3" 
showed mutation at nucleotide position 648 with a base change from A to G, 
resulting from amino acid change at position 29 (asparagine to serine). For “HPV 16 
E7 HK-4" , it had a mutation at nucleotide position 731 with a base change from T to 
A, resulting in an amino acid change at position 57 (phenylalanine to isoleucine). 
"HPV 16 E7 HK-5" showed a mutation at nucleotide position 801 with a base 
change from A to G, resulting in an amino acid change at position 80 (glutamate to 
glycine). For “HPV 16 E7 HK-6" , it had a mutation at nucleotide position 845 with 
a base change from T to G, resulting in an amino acid change at position 93 (cysteine 
to tryptophan). 
3.3.4Distrihution ofHPV16E7 Variants 
The distribution ofHPV 16 E7 sequence variants among the two groups (low-
grade group with normal or inflamed cervices, condyloma and CE^ 1; high-grade 
group with CLN 2, CIN 3 and invasive carcinoma) is illustrated in Table 15. “HPV 16 
E7 HK-3" was found to be the most commonly detected HPV 16 E7 variant among 
Chinese women. In the low-grade cervical lesions group, 22.2% was "prototype-
like", 11.1% was “HPV 16 E7 HK-2" and 66.7% was “HPV 16 E7 HK-3". ln the 
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high-grade cervical lesions group, 31.1% was “prototype-like”，1.4% was “HPV 16 
E7 HK-2" and 59.5% was "HPV 16 E7 HK-3". "HPV 16 E7 HK-1", “HPV 16 E7 
HK-4”，"HPV 16 E7 HK-5" and “HPV 16 E7 HK-6" were only found in high-grade 
、cervical lesions group. However, none of HPV 16 E7 HK-variants showed 











、 4.1 Evaluation of HPV DNA Extraction Methods for Paraffin-
Embedded Tissues 
4.1.1 PCR Evaluation of DNA Extraction Methods 
Extraction of DNA from paraffin-embedded tissue is always a challenge 
because many factors can affect the integrity of DNA. For the purpose of analysis, 
we used three parameters to access the quality ofDNA extraction. 
Firstly, the total number of samples positive for beta-globin PCR was almost 
the same among the three extractions being used (90-95%) in which the QIAGEN 
and microwave extraction methods both gave the highest positive rates. 
Secondly, the number of samples positive for the longer fragment of beta-
globin PCR was also almost the same among the three extractions being used (50-
60%) in which the microwave extraction method revealed the highest positive rate. 
Thirdly, when the intensity of the amplicons were included as a factor of 
accessing the quality of the extracted DNA, phenol-chloroform extraction showed a 
poor performance in both beta-globin PCRs whereas microwave based method was 
\ 
demonstrated to be the most efficient extraction method, providing DNA fragments 
with good quality for further analysis. This was probably because of the use of 
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microwave irradiation treatment for deparaffinisation exerts a lesser impact on the 
integrity of DNA present in the cervical tissues and thus it produced stronger PCR 
products with high intensity (Pinto and Villa, 1998). 
、 
The data were further analysed for the reliability of using beta-globin PCR to 
assess the success ofHPV DNA extraction. The MY09MY11 PCR targeting the L1 
open reading frame for HPV detection were positive only in about 20% ofthe 509-bp 
beta-globin PCR-positive cases that were extracted by the phenol-chloroform 
method. This suggested that phenol-chloroform extraction method was the most 
inferior in yielding the expected size of DNA fragments for HPV DNA detection. 
The microwave and QIAGEN spin column methods showed a better performance in 
which they carried a high positive predictive value of 67% and 90% respectively for 
509-bp beta-globin positive samples for yielding an expected size of HPV DNA. 
QIAGEN spin column also gave the highest positive rate for both HPV PCRs, 
showing that it was the most superior extraction method when using the beta-globin 
gene as an indicator for successful extraction of an equivalent length of target HPV 
DNA. 
The data also showed that HPV DNA could be detected in the 509-bp beta-
globin PCR-negative samples in all the three extraction methods. Detection of HPV 
DNA in beta-globin negative samples could be due to the presence of more copies of 
HPV DNA per cell when compared to that of beta-globin gene or the presence of 
episomal circular HPV genome. Thus, some beta-globin PCR-negative samples 
actually contained HPV DNA and such an inadequacy of using beta-globin PCR to 
access the success ofDNA extraction need to be considered. 
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Overall, QIAGEN spin column was found to be the most efficient among the 
three DNA extraction methods and gave the highest positive predictive value when 
beta-globin gene was being used for accessing the quality ofextraction methods. 
、 
4.2 Prevalence and Genotype Distribution of HPV 
4,2A Women with Normal Cervices 
A low HPV positive rate (4.2%) was found in Chinese women with normal 
cervices compared with the 10% ofHPV positive rate observed in studies from other 
parts ofthe world (Hildesheim et al., 1994). This discrepancy is probably due to the 
difference in sexual behavior between the Chinese population and the West as HPV 
is a sexually transmitted disease. Among the 25 HPV DNA-positive cases, the most 
common HPV type detected was the uncharacterized HPV types (1%), followed by 
HPV 52 (0.8%) and HPV 16 (0.7%). Because of the use of only two restriction 
enzymes for HPV typing, some of the HPV types could not be identified. With the 
use of more restriction enzymes or direct sequencing of the PCR products could be 
useful for identifying these uncharacterized HPVs into their corresponding types. A 
high positive rate for the uncharacterized HPV types was also observed in other 
studies among women with normal cervices (Astori et al., 1997; Meyer et al., 1998). 
Base on the HPV detection method being used, there is still some limitation for the 
detection of novel HPV types and their occurrence in a particular grade of cervical 
lesions needs further study. Overall, the distribution of HPVs in our normal 
population was consistent with other studies in which the low-risk HPV types were 
the predominant types whereas the high-risk HPVs were rarely found (Franco et al., 
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1999). One implication of our finding of a relative lower HPV positive rate among 
this cervical cancer "screening" population is that the use of HPV test may 
accordingly provide a higher positive predictive value for cervical neoplasia. 
、 
4,2,2 Women with Abnormal Cervical Cytologies 
The prevalence rates of HPV infection among Chinese women in this group 
who had abnormal cytology results increased with the severity of cervical lesions. A 
similar observation was found in other studies in which HPV DNA was frequently 
present in high-grade cervical lesions and cervical cancers (Comelissen et al., 1992). 
When the age distribution ofwomen with and without HPV infection was compared, 
no statistically significant difference was observed. HPV is known to be detected in 
women with a younger age. In our study population, most of the women with 
abnormal cytologies are older and this could account for the lack of difference in age 
between HPV-positive women and HPV-negative women. 
The increase in the high-risk HPVs prevalence rate was statistically significant 
for high-grade cervical lesions when compared to that in low-grade cervical lesions. 
This strongly indicates the positive role of these high-risk HPV types in the 
pathogenesis ofcervical cancer. HPV 16 was found to be the predominant HPV types 
in high-grade cervical lesions and cervical cancers. This is in accordance with 
worldwide HPV prevalence studies and had shown that HPV 16 was with a higher 
risk for the progression from low-grade to high-grade cervical lesions (Lombard et 
al., 1998; Saito et al., 1999). An unexpected high positive rate for HPV 58 was found 
in women with high-grade cervical lesions as well as cervical cancers. In contrast, 
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the positive rate for HPV 58 was very low in other HPV prevalence studies. Such a 
high detection rate for HPV 58 has been observed in other Chinese populations as 
well. In two case-control studies conducted in Taiwan, the data showed that HPV 58 
"were the most common types among HPV-positive Chinese women with high-grade 
cervical lesions and cervical cancers (Huang et al., 1997; Lin et al., 1998). A study in 
Shanghai also revealed a prevalence of HPV 58 among cervical cancer specimens 
(Liaw et al., 1997). Geographic variation in the prevalence of some less common 
HPV types has been documented. HPV 45 was apparent in Western Africa, while 
HPV 39 and HPV 59 were almost entirely confined to Central and South America 
(Bosch et aL, 1995). Therefore the impacts of infection with different less common 
HPV types in different countries are as important as that of the predominated HPV 
type 16, due to the high prevalence of these HPV types found in that population. 
As for the low-risk types, the prevalence rates of HPV 11 did not revealed a 
significant association with low-grade cervical lesions. This observation is in contrast 
with other studies，showing a higher detection rate of low-risk HPVs in low-grade 
cervical lesions than in high-grade cervical lesions or cervical cancers (Herrington, 
1994). 
When a non-genotype discriminating assay (MY09MY11 PCR) was used to 
detect HPV DNA from women with abnormal cytology results, the sensitivity, 
specificity, positive and negative predictive values (67%, 71%, 63.3%, 74.3%) for 
the presence of high-grade cervical lesions are too low for routine clinical 
application. However, when the detection of HPV was down to type-specific level, 
the presence of HPV 16 provided a specificity of 96.4% and a positive predictive 
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value of86.6%. Thus, type-specific HPV detection may have a role in routine use for 
women with abnormal cervical cytology results. The high-risk HPV 16 carried a high 
positive predictive value and with an odds ratio of 12.05 for high-grade cervical 
、lesions，further indicating its oncogenic property in the development of cervical 
cancers and the detection of HPV 16 may possess a higher risk for high-grade 
cervical lesions. 
4,23 Women with Cervical Cancer 
HPV DNA was frequently detected by PCR with a positive rate of > 90% in 
cervical cancers (Bosch et al., 1995; Walboomers and Meijer, 1997). Our positive 
rate for HPV DNA in the 20 paraffin-embedded tissues was 60% which is much 
lower than the positive rates (>90%) reported from other studies. The reason for this 
may be due to our study design. The 20 paraffin-embedded samples of cervical 
cancers were intended for the assessment of DNA extraction methods. Thus, we 
deliberately used tissues that had been stored for more than seven years. These 
tissues are expected to provide sub-optimal DNA quality and this may account for 
the observed lower HPV positive rate. Because of this, these paraffin-embedded 
cases were not included to the genotype distribution analysis. Nevertheless, among 
the HPV-positive samples，we still observed a high prevalence ofHPV types 16 and 
58 in women with cervical cancers, suggesting the contribution of these oncogenic 
HPV types to the development of cervical cancers. 
4.3 Sequence Variation ofHPV16 E7 Gene 
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Analysis of intratype variations is important for epidemiological studies in 
which sequence variations can be used as markers for monitoring HPVs in a defined 
population. Infection with specific types ofhuman papillomavirus is the main risk for 
^precancerous lesions and cervical cancers. Because of the alternation in the 
biological and functional properties of the HPV 16 E7 variants, they may be 
positively or negatively associated with cervical cancers. Some recent investigations 
have evaluated the association of specific HPV 16 E7 variants with the development 
of high-grade cervical lesions and cervical cancers, confirming the differences in 
biological function among each variant and from the prototype. 
In the present study, a total of seven HPV 16 E7 HK variants were found in 
which three ofthem, "HPV 16 E7 HK-1", "HPV 16 E7 HK-2" and "HPV 16 E7 HK-
3" had mutations within the conserved region two. Another variant, "HPV 16 E7 
HK-6" had a mutation within the Cys-X-X-Cys motif. Previous studies of mutations 
within the pRb binding site, the casein kinase II phosphorylation region and the Cys-
X-X-Cys motifs revealed differences in the transforming potential (Jones et al., 1990; 
Watanabe et al., 1990; Pahel et al., 1993). Our analysis showed that the amino acids 
at or adjacent to the pRb, casein kinase II phosphorylation site and Cys-X-X-Cys 
motifs ofHPV 16 E7 is highly conserved and mutations within this E7 region might 
have biological significant. 
Among our detected variants, three HPV 16 E7 amino acid changes were 
identified in positions crucial for pRb binding and for casein kinase II 
phosphorylation. The amino acid changes at position 28 of"HPV 16 E7 HK-1" (A-> 
C, Leu28Phe) and at position 29 of"HPV 16 E7 HK-2" (A— C, Asn29His) have 
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previously shown to associate with high-grade lesions (FirzlafF et al., 1989; Fujinaga 
et al., 1994). Substitutions at amino acid positions 28 and 29 were shown to affect 
the phosphorylation by casein kinase II, which in turn alter the transforming 
、properties of E7 by modulating the interaction of E7 to other cellular proteins 
(Icenogle et al., 1991). Therefore "HPV 16 E7 HK-1" and "HPV 16 E7 HK-2" could 
be important for the transforming activity ofE7 protein. 
The nucleotide and amino acid variations ( A ^ G, Asn29Ser) observed in our 
"HPV 16 E7 HK-3" variant confirms those reported by Song et al (1997) in which it 
was frequently detected in high-grade lesions and cervical cancers. Such amino acid 
change has been reported in in vitro mutational studies that could affect the 
biological properties of HPV and the phosphorylation of casein kinase II. In our 
study, "HPV 16 E7 HK-3" was found in 78.6% of women with high-grade lesions, 
but has yet reached statistical significance. It is possible that "HPV 16 E7 HK-3" 
might also have altered biological properties. However, to determine the effect ofthis 
amino acid change on the biological alteration or malignant transforming potential of 
‘‘HPV 16 E7 HK-3", further functional studies are needed by transformation assay. 
The change form cysteine to tryptophan at amino acid position 93 within the 
Cys-X-X-Cys motif of "HPV 16 E7 HK-6" variant may have an implication in 
transformation efficiency. In the Cys-X-X-Cys motifs, reduced transforming activity 
was observed with sequence variation at amino acids of 58 and 91 (cysteine to 
glycine) (Edmonds and Vousden, 1989). Meulen had demonstrated the inability of 
cysteine mutant to transform cell and zinc binding but without any change on pRb 
binding. It has been suggested that cysteine mutant could still bind to pRb but was 
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not sufficient for transcription factor E2F dissociation (Meulen et al., 1993). E7 in a 
dimeric form with intact Cys-X-X-Cys motifs was required for the disruption of 
pRb-E2F complex and these motifs, especially at amino acid positions 91 to 94 was 
、important for the E7 protein to form a stable structure by binding with zinc 
(McIntyre et al.，1993). As mutation in "HPV 16 E7 HK-6" was identified within this 
crucial region for maintaining the stability of the HPV, further site-directed 
mutagenesis study of this "HPV 16 E7 HK-6" variant may provide additional 
information in determining the stability of HPV within the zinc binding motifs and 
its oncogenic potential. 
The seven HPV 16 E7 HK variants being found in this study were not 
significantly associated with the degree of cervical lesions, however this does not 
necessary imply they are of equal oncogenicity and the effect of their biological 
functions still remains to be defined. As our study is a cross-sectional study, infection 
with a particular variant cannot reveal any persistence or progression of cervical 
lesions. Further prospective studies on the association of these variants to malignant 
progression will be crucial for understanding the oncogenic potential of each 
variants. Apart from the association of particular HPV 16 E7 variants with the 
increase in risk of high-grade lesions, other cofactors also contribute to the 
development ofcervical cancers. Previously, an increased in susceptibility to HPV 16 
infection with greater risk for cervical cancers in Caucasian population is associated 
with a particular HLA halotype (Odunsi et al., 1996). The effect of cofactors could 
provide an explanation for the insignificant increase in risk of HPV 16 E7 HK 
variants for high-grade cervical lesions and therefore other cofactors should be taken 
into account in examining the association between HPV 16 E7 variant infection and 
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cervical cancers. 
Although the number of samples we examined is small, our results suggest that 
、infection with "HPV 16 E7 HK-3" may be related to progression to high-grade 
cervical lesions. As the current study was still limited by sample size, a reliable 
estimate of the prevalence of particular HPV 16 E7 HK variants in high-grade 
cervical lesions and cervical cancers can further be obtained by sequencing more 
HPV 16 samples. Comprehensive research is required to elucidate the biological 
understanding of HPV 16 E7 HK variants and to search for the individual risk 
association of each variant as well as their prevalence in the Chinese population. 
This study supports the need to study women with HPV 16 E7 HK variant infections 
in order to define more precisely the risk of a particular HPV 16 E7 HK variant 
which may predispose individuals to the development ofhigh-grade cervical lesions 













The first part ofthe study aims at evaluating three DNA extraction methods for 
paraffin-embedded tissues revealed that QIAGEN spin column extraction was with 
the best performance, providing the expected length of DNA fragments for human 
and HPV PCRs. Besides, it has the highest positive predictive value when beta-
globin gene was being used as an indicator for successful HPV DNA extraction. 
For the study of prevalence and genotyping distribution of HPV, the HPV 
positive rate showed a statistically significant increase in risk for a high-grade 
cervical lesions and cervical cancers, showing that HPV plays an aetiological role in 
cervical cancers. In Chinese population, HPV 16 was found to be the most 
predominant HPV type, which is in accordance with the worldwide studies. Besides 
an unusual finding was observed that HPV 58 was the second most common HPV 
type in Chinese women with high-grade cervical lesions and cervical cancers, 
whereas only a small percentage of HPV 58 was detected in Europe and United 
States. The high prevalence ofHPV 58 among Chinese women has an implication on 
the design of HPV detection methods and further study on its oncogenic potential 
could provide more information of its association with the development of cervical 
cancers. In addition, HPV types 16, 33 and 58 infection showed a significant 
association with high-grade lesions, implicating the positive role of these high-risk 
and intermediate-risk HPVs for cervical cancers. 
For the study on the sequence variation of HPV 16 E7 oncogene, a total of 
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seven variants were identified. For the "HPV 16 E7 HK-1", "HPV 16 E7 HK-2" and 
"HPV 16 E7 HK-3" variants, mutations were found to be located adjacent to the 
crucial region of pRb binding and casein kinase phosphorylation sites whereas 
、mutation was located at the Cys-X-X-Cys motif in "HPV 16 E7 HK-6" variant. 
Although the seven HPV 16 E7 HK variants being found in Hong Kong were not 
significantly associated with the degree of cervical lesions in this study, infection 
with "HPV 16 E7 HK-3" variant may be related to the risk for high-grade lesions and 
"HPV 16 E7 HK-6" may have a different in transformation ability. Nevertheless, 
additional samples for HPV 16 need to be further analysed for confirmation. Further 
studies of in vitro mutagenesis and transformation assay would be helpful for the 
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Table 1. Sequences ofOligonucleotide Primers for Human Beta-globin Gene 
Primer Set Sequence (5,-3,) Size of Amplicon (bp) 
•••pco3 ; ? ; . X i 5X5XX5 f ^ ^< i 5X5 ' ^S i i i £ l ' , ^09 
PC07 -5，GAAAACATCAAGGGTCCCAT 3’ 
Beta-GPl +5' ATGGTGCACCTGACTCCTGAGG3' 355 
Beta-GP2 -5，GCCATCACTAAAGGCACCGAGC 3 ‘ 
一^——<————**-—."'!<*,!*—"“'-*-"“"-,— ""-'-****"""***"***"*™""—""""'—"""'"'"""**""""'-"""」‘"""」****"""""""""""^"""""""*"***"""""""""""™**"""""* IULmUULJL,l UULIUI |_UULJ»rL._」_IULmUU」_L 
73 
Table 2. Sequences ofOligonucleotide Primers for HPV L1 Open Reading Frame 
Primer Set Sequence (5'-3') Size of Amplicon (bp) 
•.…MYii ^ F i i ^ S ; i S S S ^ i S ^ ^ ^ i ^ ^ S S S f i S i r F 450 
、MY09 -5, CGTCCMARRGGAWACTGATC 3， 
(M=A or C; R=A or G; W=A or T; Y=C or T) 
GP5+ +5, TTTGTTACTGTGGTAGATACTAC 3, 150 
GP6+ -5，GAAAAATAAACIGTAAATCATATTC 3， 
^^^^^_^^^^^^^^^^^j^j^^^j^^^^^^^j^j^j^j^j^j^^^j^j^^^^^^yyy^„jyy^yyyyyyf)fyyYy"H._"_««______MM**»w^wM^>iw^wMMiwwwwMWWWMWWWWwvwwwwwuifmnnAnmiJuuuuuuinfuuuwuuinnnnfmJLJULJLJLmLJ 
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Table 3a. Homology Analysis o fMY l l (forward) Degenerated Primer for the L1 
Open Reading Frame of40 Genital HPVs 
HPV Type MY11 forward primer 5'^3' Nucleotide GeneBank 
Position Accession No. 
- ¾ ¾ ^ ^ ¾ ¾ ¾ ¾ " ^ ¾ ¾ ^ ¾ ¾ ¾ ^ 
^pV6b 6723 PAPA6B 
HPV11 . .T 6707 PPH11 
Hpvi3 C 6669 HPVT13DNA 
HPV16 •••• C. .C 6582 PPH16 
HPV18 6558 PAPHPV18 
HPV2 6 6533 HPV2 6 
HPV30 C 6597 HPV30 
HPV31 ..T C 6500 PPH31A 
HPV32 A..C. .C 6817 HPV32 
HPV33 A 6539 PPH33CG 
HPV34 A 6444 HPV34 
HPV35 A..C 6522 PPH35CG 
HPV39 C. .C 6585 PPHT39 
HPV4 0 C 6718 HPV4 0 
HPV42 A C 6782 PPHPAPV42A 
Hpv43 * HPU1250411 
HPV44 !!c!!...c. .C 女 HPU1249311 
HPV45 C 6762 HPV45 
HPV51 . .G C * PPHDNA 
HPV52 . .G C. .C 6003 HPV52 
HPV53 6504 HPV53 
HPV54 A 6541 HPU37488 
HPV55 . .G C. .C 6627 HPU31791 
HPV56 A..C 6539 HPV56 
HPV57 6684 PAHPV57 
HPV58 A 6588 PPH58 
HPV59 . .T T TA 6551 HPV59VG 
HPV61 C. .C 6712 HPU31793 
HPV66 C 6588 HPU31794 
HPV68 C 女 HPVL1 
HPVCP141 A C * HPU12476 
HPVCP6108 * HPU124788 
HPVCP8 0 61 * HPU124791 
HPVCP8304 * HPU124804 
HPVLVX100 * HPU124850 
HPVLVX160 * HPU124860 
HPVMM4 * HPU12488 
HPVMM7 * HPU12489 
HPVMM8 . .G.G * HPU12490 
HPVMM9 ^ HPU12491 
The primer sequences were in boldface type with the corresponding HPV sequence 
alignments underneath. Nucleotide homology was indicated with a period, and 
mismatches were indicated with the nucleotide change in the corresponding 
sequence. 
*HPV with partial sequence where nucleotide position was not available. 
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Table 3b. Homology Analysis ofMY09 (reverse) Degenerated Primer for the L1 
Open Reading Frame of40 Genital HPVs 
HPV Type MY09 reverse primer 5'^3' Nucleotide GeneBank 
Position Accession No. 
5iS^SSiSSiir_^S^iSiY^^iSii 
^PV6b 7171 PAPA6B 
HPV11 7156 PPH11 
HPV13 '.TG 7123 HPVT13DNA 
Hpvi6 T 7069 PPH16 
HPV18 :••:•• T 7012 PAPHPV18 
HPV2 6 . .C..T..T T 6987 HPV26 
HPV30 .TG T. .G..T..G.. 7045 HPV30 
HPV31 . .A T 6951 PPH31A 
HPV32 .TA T 7265 HPV32 
HPV33 6987 PPH33CG 
HPV34 '.TA..T.... C 6901 HPV34 
HPV35 ..G C 6973 PPH35CG 
HPV39 G..T 7039 PPHT39 
HPV4 0 T..T T 7172 HPV4 0 
HPV42 ' T. . . T T 7230 PPHPAPV42A 
HPV43 GCG. .T GGT * HPU1250411 
HPV44 .TA T * HPU1249311 
HPV45 ..A T 7216 HPV45 
HPV51 ..A T. C...T..G.. 女 PPHDNA 
HPV52 .TA..T 7051 HPV52 
HPV53 .TG 7042 HPV53 
HPV54 G. . 6992 HPU37488 
HPV55 .TA T 7081 HPU31791 
HPV56 .TA T T 6987 HPV5 6 
HPV57 G. .T..G. . 7132 PAHPV57 
HPV58 7036 PPH58 
HPV59 7005 HPV59VG 
HPV61 ..C 7166 HPU317 93 
HPV66 .T 7037 HPU31794 
HPV68 T..T. .G. .T. .G. . * HPVL1 
HPVCP141 * HPU12476 
HPVCP6108 •••///. ^ HPU124788 
HPVCP8 0 61 * HPU124791 
HPVCP8 304 * HPU124804 
HPVLVX100 * HPU124850 
HPVLVX160 * HPU124860 
HPVMM4 * HPU12488 
HPVMM7 * HPU12489 
HPVMM8 * HPU12490 
HPVMM9 * HPU12 4 91 
The primer sequences were in boldface type with the corresponding HPV sequence 
alignments underneath. Nucleotide homology was indicated with a period, and 
mismatches were indicated with the nucleotide change in the corresponding 
sequence. 
*HPV with partial sequence where nucleotide position was not available. 
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Table 4a. Homology Analysis of GP5+ (forward) General Primer for the L1 Open 
Reading Frame of40 Genital HPVs 
HPV Type GP5+ forward primer 5'^3' Nucleotide GeneBank 
Position Accession No. 
i Y iS i ^SS^T ^ S ^ i S i ^ i ^ 6 TAC 
^pV6b C. . 6764 PAPA6B 
HPV11 C. . 6749 PPH11 
HPV13 A. .T 6711 HPVT13DNA 
HPV16 T. .T 6624 PPH16 
Hpvi8 C. . 6600 PAPHPV18 
HPV2 6 CT GT..T C.. 6575 HPV2 6 
HPV30 T..G..C.. C. . 6639 HPV30 
HPV31 C. . 6542 PPH31A 
HPV32 . . .C.A T. .G 6859 HPV32 
HPV33 . . .C.A T. .G 6581 PPH33CG 
HPV34 . . .T.A T 6486 HPV34 
HPV35 A. .T A. . 6564 PPH35CG 
HPV3 9 . . .C T..G..C 6627 PPHT39 
HPV4 0 A. .T C. . C. . 6760 HPV4 0 
HPV42 . . .T.A T 6824 PPHPAPV42A 
HPV43 A C. . * HPU1250411 
HPV44 T * HPU1249311 
HPV45 A. .G. .C 6604 HPV4 5 
HPV51 . . .A CT GT. .T 女 PPHDNA 
HPV52 C. .A. .T..G C. . 6645 HPV52 
HPV53 A T. .G C. . 6636 HPV53 
HPV54 . . .T.A. .A. .T C. . 6587 HPU37488 
HPV55 T 6669 HPU31791 
HPV56 A. 6581 HPV56 
HPV57 . .CC.A. .A G..C..C.. 6726 PAHPV57 
HPV58 C T C. . 6630 PPH58 
HPV59 . . .T.A. .A. .T 6593 HPV59VG 
HPV61 A. .C. .T..G C. . 6754 HPU31793 
HPV66 T. .G 6631 HPU31794 
HPV68 . . .C C. .T..G A. . * HPVL1 
HPVCP141 . . .A G..C * HPU12476 
HPVCP6108 C.. 女 HPU124788 
HPVCP8 0 61 A. .A. .T. .G. .C. . AT. * HPU124791 
HPVCP8304 A G * HPU124804 
HPVLVX100 G..A. .T * HPU124850 
HPVLVX160 . . .A G. .C * HPU124860 
HPVMM4 ...A T GT. .T. .C * HPU12488 
HPVMM7 A. .T * HPU12489 
HPVMM8 C..G G C. . * HPU12490 
HPVMM9 . . .T.A T * HPU12491 
The primer sequences were in boldface type with the corresponding HPV sequence 
alignments underneath. Nucleotide homology was indicated with a period, and 
mismatches were indicated with the nucleotide change in the corresponding 
sequence. 
*HPV with partial sequence where nucleotide position was not available. 
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Table 4b. Homology Analysis ofGP6+ (reverse) General Primer for the L1 Open 
Reading Frame of40 Genital HPVs 
HPV Type GP6+ reverse primer 5'^3' Nucleotide GeneBank 
Position Accession No. 
i^iiSiSj^^iiSrdiSjSiiii^SSir TATTC 
^pV6b T C. . 6902 PAPA6B 
HPV11 A.C. • 6887 PPH11 
HPV13 T A 6855 HPVT13DNA 
HPV16 6765 PPH16 
HPV18 C 6744 PAPHPV18 
HPV2 6 T T T 6719 HPV2 6 
HPV3 0 C.C T 6777 HPV3 0 
HPV31 T T A 6683 PPH31A 
HPV32 T T 6997 HPV32 
HPV33 C G 6719 PPH33CG 
HPV34 C.C C.GG C. . 6633 HPV34 
HPV35 6705 PPH35CG 
HPV39 T T C. . 6772 PPHT39 
HPV4 0 C A.C. . 6904 HPV4 0 
HPV42 T T..C.C 6962 PPHPAPV42A 
Hpv43 T C.G * HPU1250411 
HPV44 C T G. . . A.C. . * HPU1249311 
HPV45 6748 HPV45 
Hpv51 T..C..T C. . * PPHDNA 
HPV52 T A. . . . 6783 HPV52 
HPV53 C.C... T T 6774 HPV53 
HPV54 T 6726 HPU37488 
HPV55 C G...A.C.. 6813 HPU31791 
HPV56 C. . . T T 6719 HPV56 
HPV57 G C 6864 PAHPV57 
HPV58 C G 6768 PPH58 
HPV59 T C A 6737 HPV59VG 
HPV61 T..C A.C. . 6895 HPU31793 
HPV66 C.C GT 6769 HPU31794 
HPV68 T C * HPVL1 
HPVCP141 . . . .T T * HPU1247 6 
HPVCP6108 .G..T GG * HPU124788 
HPVCP8 0 61 ....T T..C A.... * HPU124791 
HPVCP8304 .G C * HPU124804 
HPVLVX100 ....T C A.... * HPU124850 
HPVLVX160 ....T T 女 HPU124860 
HPVMM4 T T..C. .T * HPU12488 
HPVMM7 .C..T C G * HPU12489 
HPVMM8 .G..T C * HPU12490 
HPVMM9 • . .G. .C . A.C. . : HPU12 4 91 
The primer sequences were in boldface type with the corresponding HPV sequence 
alignments underneath. Nucleotide homology was indicated with a period, and 
mismatches were indicated with the nucleotide change in the corresponding 
sequence. 
*HPV with partial sequence where nucleotide position was not available. 
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Table 5. Predicted Restriction Fragment Length Patterns for 38 Genital HPVs 
Digested with Rsa I and Dde I ofMY09/MYll PCR Products. 
HPV Undigested Fragment Length(s) ofPCR Products 
、Genotype (bp) Rsa I Digested (bp) DJ(^ i pigestedj;bp) 
6b AA9 677 72； 149； 161 67, 382 
11 449 26，72，135, 216 2, 447 
13 455 11、73，135, 175 62，67, 326 
16 452 70， 72, 310 452 
18 455 38，72, 85, 125, 135 23, 432 
26 455 18, 72’ 365 455 
31 452 2, 167，283 72, 380 
32 449 72, 161, 216 21, 108，320 
33 449 39，72，102, 236 52, 77, 320 
34 458 15, 96, 161, 186 8’ 88, 151, 211 
35 452 42, 72, 161, 177 23, 135, 294 
39 455 72, 123，260 131, 324 
40 455 90, 365 158, 297 
42 449 72, 135, 242 108, 341 
44 455 72, 161, 222 46, 112, 297 
45 455 45, 72，338 131, 324 
51 452 72, 380 90, 362 
52 449 449 92, 357 
53 449 449 85，158, 206 
54 452 72, 117，125, 138 452 
55 455 57，72, 161，165 46, 85, 101, 111, 112 
56 449 18，49, 72, 310 142, 307 
57 449 449 46, 50, 142, 211 
58 449 32，111, 306 101，348 
59 452 452 452 
61 455 18, 72, 180, 185 455 
66 449 449 158, 291 
68 455 38，72，85, 260 455 
CP141 455 29, 72, 123, 231 455 
CP6108 452 72, 380 54，152, 246 
CP8061 452 72, 380 132，320 
CP8304 452 452 452 
LVX100 455 18, 72，365 155，297 
LVX160 455 29，72，123, 231 455 
MM4 455 72, 383 167, 288 
MM7 452 72，380 452 
MM8 452 142，310 90，142, 220 
MM9 4 ^ 96, 161, 201 215, 243 
79 
Table 6. Sequences of Type-specific Oligonucleotide Primers for E7 Open 
Reading Frame ofHPV 16 
Primer Sequence (5,-3,) Genomic Size of Amplicon 
、set Location^ (bp) 
0 ^ . i � : T : . ? ^ ; i 5 5 5 i J ? ? 5 5 X K S ^ i S ^ i £ � ^ � 501 572 
PCR E7-2: -5, ACGCATGTGCTGTCTCTGTT 3, 1072 
Inner E7-3: +5，TGCAGATCATCAAGAACACG3' 521 368 
PCR E7-4: -5，/O^TGGTACCTGCAGGATCAG 3 ’ 888 
, • • r rBMtfWOTTnnni_igmwna 
^Nucleotide positions were based on HPV 16 prototype available in the GeneBank 
(Accession number: K02718). 
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Table 7. Positive Rates and Amplicon Intensity ofBeta-globin PCR According to 
DNA Extraction Methods 
DNA Extraction PC03/07 (509 b ^ Beta-GPl/Beta-GP2 (355 bp) 
、Method 3+ 2+ 1+ No. of 3+ 2+ 1+ No. of 
、 Positive Positive 
(o/o) n=20 (o/o) n=20 
Phenol- 0 4 6 10(50) 10 5 3 18 (90) 
Chloroform 
Microwave 4 4 4 12 (60) 12 4 3 19(95) 
QIAGEN Spin 0 5 5 10 (50) 12 4 3 19 (95) 
Column 
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Table 8. Positive Rates ofHPV PCRs 
Extraction Methods No. ofHPV DT^os i t i ve (%) 
No. of MY09MY11 PCR GP 5+/GP6+ PCR 
Samples (n) (450 bp) d^Obp) 
Phenol-Chloroform 
509 bp p—globin PCR Positive 10 2 (20) 5 (50) 
509 bp p-globin PCR Negative 10 7 (70) 3 (30) 
Microwave 
509 bp P-globin PCR Positive 12 8 (67) 10 (83) 
509 bp p-globin PCR Negative 8 1 (25) 2 (25) 
QIAGEN Spin Column 
509 bp P-globin PCR Positive 10 9 (90) 9 (90) 
509 bp p—globin PCR Negative 10 4 (40) 6 (60) 
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Table 9. Distribution ofHPV Genotypes among 593 Chinese Women with Normal 
Cervices 
HPV Genotype Number (%) ofWomen with 
、 Normal Cervices 
HPV 6b 1 (0.2) 
HPV 16 4(0.7) 
HPV 18 1 (0.2) 
HPV31 1 (0.2) 
HPV 52 5 (0.8) 
HPV 53 3 (0.5) 
HPV 58 2 (0.3) 
HPV 59 2 (0.3) 
HPV CP141 2 (0.3) 
HPV CP8304 2 (0.3) 
HPV MM7 1 (0.2) 
HPV MM8 1 (0.2) 
Uncharacterized 6 (1.0) 
Negative 568 (95.8) 
HPV-Positive^ 25 (4.2) 
Regardless of single or double-type HPV infection. 
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Table 10. Prevalence and Genotype Distribution ofHPV in 440 Chinese Women 
with Various Grades of Cervical Lesions 
HPV Mection Number (Vo^  ofWomen with 
、 Normal/ Condyloma CDST1 CD^2 O N 3 Carcinoma Total 
Biflamed 
Cervix 
Positive' 15(15.5) 32 (28.3)~~26 (61.9)~~37(61.6)~~72 (69.2) 17(70.8) 199 (45.2) 
HPV6b 2(2.1) 0 0 0 0 1 (4.2) 3 (0.7) 
HPV 11 1 (1.0) 1 (0.9) 4(9.5) 2 (3.3) 0 0 8(1.8) 
HPV 16 2(2.1) 6 (5.3) 1 (2.4) 12(20) 35 (33.7) 11 (45.8) 67(15.2) 
HPV 18 1(1.0) 3(2.7) 3(7.1) 4(6.7) 1(1.0) 1 (4.2) 13(3.0) 
HPV 26 0 1 (0.9) 0 0 0 0 1 (0.2) 
HPV 29 0 0 1 (2.4) 0 0 0 1 (0.2) 
HPV31 1(1.0) 1(0.9) 2(4.8) 1(1.7) 4(3.8) 2(8.3) 11(2.5) 
HPV 33 0 1 (0.9) 1 (2.4) 0 5 (4.8) 2 (8.3) 9(2.0) 
HPV 34 0 1 (0.9) 0 0 0 0 1 (0.2) 
HPV 39 0 0 2(4.8) 1 (1.7) 3 (2.9) 0 6(1.4) 
HPV 52 0 1 (0.9) 4(9.5) 4(6.7) 3 (2.9) 0 12 (2.7) 
HPV 58 0 6 (5.3) 2 (4.8) 5 (8.3) 14(13.5) 2 (8.3) 29(6.6) 
HPV 59 0 0 0 2 (3.3) 0 0 2 (0.5) 
HPV61 2(2.1) 0 1 (2.4) 0 0 0 3 (0.7) 
HPV 66 0 0 0 0 1 (1.0) 0 1 (0.2) 
HPV 68 0 2(1.8) 0 0 0 0 2(0.5) 
HPV CP8304 0 0 0 2 (3.3) 0 0 2 (0.5) 
HPVMM7 0 0 0 0 1 (1.0) 0 1 (0.2) 
HPVMM9 0 0 0 0 1 (1.0) 0 1 (0.2) 
Uncharacterized 6(6 .2) 10(8.8) 6(14.3) 5(8.3) 10(9.6) 0 37(8.4) 
Negative 82 (84.5) 81 (71.7) 16(38.1) 23(38.3) 32 (30.8) 7(29.2) 241 (54.8) 
Total 97 113 42 60 104 24 440 
Regardless of single or double-type HPV infection. 
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Table 11. Odds Ratio ofHPV Infection for High-grade Cervical Lesions 
1 ^ No . o f No. o f P o s i t i v e 7 ^ Odds ^ P Value 
Genotype Samples High-grade Low-grade Rat io Confidence 
^ Cervical Lesions^ Cervical Lesions^ M e r v a l 
~ n 8 2 (25) 6 ( 7 5 ) 0 4 4 0.66-2.44 0 ^ ~ 
、 
16 67 58 (86.6) 9 (13.4) 12.05 5.55-26.99 0.00^ 
18 13 6 ( 4 6 . 2 ) 7 (53.8) 1.15 0.34-3.90 0.80^ 
31 11 7 (63.6) 4 ( 3 6 . 4 ) 2.40 0.62-9.90 0.16° 
33 9 7 (77.8) 2 (22.2) 4.83 0.91-34.07 0.04。 
39 6 2 ( 3 3 . 3 ) 4 ( 6 6 . 7 ) 0 .67 0.08-4.27 1.00。 
52 12 7 (58.3) 5 (41.7) 1.91 0.53-7.05 0.27^ 
58 29 21 (72.4) 8 ( 2 7 . 6 ) 3 .84 1.57-9.67 0.001^ 
Uncharacterized 37 15 (40.5) 22 (59.5) 0.91 0.43-1.89 0 .78 ' 
^igh-grade cervical lesions included CrN 2, CIN 3 and carcinoma. 
^Low-grade cervical lesions included normal or inflamed cervices, condyloma and CD^ 1. 
eBy Fisher’ s exact test. 
dBy X2 test. 
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Table 12. Prevalence ofHPV Risk-type Infections According to Severity of 
Cervical Lesions 
~~~HPV Risk Number (%) ofWomen with 
、 Group Normal O N l O N 2 O N 3 Carcinoma Total HPV 
High-risk' 12 (30.8) 4 (20.0) 16(50.0) 36(57.1) 12(80.0) 80(47.3) 
Mermediate- 7(17.9) 6(30.0) 9(28.1) 17(27.0)) 2(13.3) 41(24.3)) 
riskb 
Low-riskb 4(10.3) 4(20.0) 2(6.3) 0(0) 1(6.7) 11(6.5) 
Uncharacterisd 16(41.0) 6(30.0) 5(15.6) 10(15.9) 0(0) 37(21.9) 
Total 39 20 32 63 15 169 
aHigh-risk group included HPV types 16 and 18. 
^Intermediate-risk group included HPV types 52 and 58. 
^Low-risk group included HPV types 6b and 11. 
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Table 13. Sensitivity, Specificity and Predictive Values ofHPV Detection for High-
grade Cervical Lesions among Women with Abnormal Cervical Cytology 
Results^ 
、HPV Types No. ofHPV Positive for High-grade Cervical Lesions 
No. of Sensitivity Specificity Positive Negative 
Samples (n) (%) (%) Predictive Value Predictive Value 
m (%) 
11 8 1.1 97.6 25.0 56.9 
16 67 30.9 96.4 86.6 65.2 
18 13 3.2 97.2 46.2 57.4 
31 11 3.7 98.4 63.6 57.8 
33 9 3.7 99.2 77.8 58.0 
39 6 1.1 98.4 33.3 57.1 
52 12 3.7 98.0 58.3 57.7 
58 29 11.2 96.8 72.4 59.4 
Uncharacterized 37 8.0 91.3 40.5 57.1 
HPV-positive 199 67.0 71.0 63.3 74.3 
^igh-grade cervical lesions included CJN 2，CJN 3 and carcinoma. 
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Table 14. Distribution ofHPV Genotypes among 20 Chinese Women with Cervical 
Cancer 
HPV Genotype Number (%) ofWomen with 
、 Cervical Cancers 
HPV 16 8(40) 
HPV 58 2 (10) 
Uncharacterized^ 2 (10) 
Negative 8 (40) 
HPV-Positive 12 (60) 
apCR amplicon intensity was too low to allow a confident genotype identification. 
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Table 15. Distribution ofHPV 16 E7 Variants According to the Degree of 
Cervical Lesion. 
Variants No.of NumberofPositive (%) Odds ^ Pvalue 
、 Samples Low-grade High-grade Ratio Confidence 
(n) Cervical Cervical Interval 
Lesions^ Lesions^ 
Prototype-like ^ 4 (22.2) 23 (31.1) 0 ^ 0.15-2.25 0.41^ 
HPV 16 E7 HK-1 1 0(0) 1 (1.4) 0 0-71.59 1.0。 
HPV 16 E7 HK-2 3 2(11.1) 1 (1.4) 8.71 0.57-258.87 0.10' 
HPV 16 E7 HK-3 56 12 (66.7) 44 (59.5) 1.44 0.44-4.84 0.50^ 
HPV 16 E7 HK-4 3 0 (0) 3 (4.1) * 0-9.35 0.38^ 
HPV 16 E7 HK-5 1 0(0) 1(1.4) * 0-71.59 1.0。 
HPV 16 E7 HK-6 1 0(0) 1(1.4) * 0-71.59 1.0。 
^Low-grade cervical lesions included normal or inflamed cervices, condyloma and CIN 1. 
bHigh-grade cervical lesions included CIN 2, CIN 3 and carcinoma, 
^ y Fisher's exact test, 
dfiy x^ test. 
*Odds ratio cannot be estimated as the number of positive for low-grade cervical 
lesions are zero. 
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A. M 1 2 3 4 N 
b p _ ^ | B H ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ H 
‘ 個 
B. M 1 2 3 4 N 
^^^^^^^^^^^^^^^^^^^^^^^^^^^1 
f^^^^^^^^m 
b p _ ^ H H | | ^ ^ ^ ^ ^ ^ ^ ^ H 
b p _ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ H 
C. M 1 2 3 4 N 
603 hp_Jf^K^K^^^^^m 
m^K^^^^^^^^^^^^^^^^^^^^^^^^m 
对0 b p j P ^ ^ ^ ^ ^ ^ ^ ^ | 
Fig. 1. Optimisation ofannealing temperature for beta-globin 
PC03/PC07 PCR with primer concentration at 0.25 mM. 
Annealing temperatures used were (A) 53。C，(B) 55。C，(C) 57®C. 
Lanes: H Marker 0-174-RF DNA digested by Hae III; 
1-4, White bloodcelllysate dilutedto 10^, I0^, 10^, 10^cells/5-i^l inoculum： 
N, Double distilled water as negative control 
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A. i ii 
M 1 2 3 4 N 1 2 3 4 
^ ^ ^ ^ ^ ^ ^ ^ H 一~{ ^ 
b p — ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ l 
B. i ii 
M 1 2 3 4 N 1 2 3 4 
^ • I ^ H 
bp 、 ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ J 
310 b p _ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ H 
Fig. 2. Optimisation ofprimer concentration for beta-globin PC03/PC07 
PCR with annealing temperature at 5TC. Primer concentrations used 
were (A.i) 1 mM，(A.i i) 0.5 m M ; (B.i) 0.25 mM，(B.i i) 0.125 m M . 
Lanes: M, Marker 0-174-RF DNA digested by Hae III; 
1-4’ White bloodcell lysate dilutedto 10^ 10\ 10^ 10^ cells/5-pil inoculum; 
N’ Double distilled water as negative control. 
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A. M 1 2 3 4 N 
b p ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ H 
b p _ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ H 
B. M 1 2 3 4 N 
b p _ ^ | P ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ H 
" ' ^ ^ ^ m 
C. M 1 2 3 4 N 
603 b p _ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ H 
310 b p _ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ H 
Fig. 3. Optimisation of annealing temperature for beta-globin 
Beta-GPlABeta-GP2 PCR with primer concentration at 0.25 mM. 
Annealing temperatures used were (A) 53®C, (B) 55^C, (C) 5TC. 
Lanes: M’ Marker 0-174-RF DNA digested by Hae III; 
1-4’ White bloodcelllysate dilutedto I0^, 10^, I0^, 10^cells/5-|xl inoculum; 
N, Double distilled water as negative control 
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A. i ii 
M 1 2 3 4 N 1 2 3 4 
603 b p _ J ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ M 
310 b p ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ H 
B. i ii 
M 1 2 3 4 N 1 2 3 4 
603 b p _ ^ H ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ H 
" ^ B 
Fig. 4. Optimisation of primer concentration for beta-globin 
Beta-GPl/Beta-GP2 PCR with annealing temperature at 57。C. 
Primer concentrations used were (A.i) 1 mM，(A.ii) 0.5 mM; 
(B.i) 0.25 mM, (B.ii) 0.125 mM. 
Lanes: M’ Marker 0-174-RF DNA digested by Hae III; 
1-4’ White bloodcell lysate dilutedto 10\ 10\ 10^ 10^cells/5-jul inoculum; 
N’ Double distilled water as negative control 
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A. M 1 2 3 4 5 6 N 
b p ^ M H ^ ^ ^ ^ ^ ^ ^ H 
b p _ ^ m n m m i ^ i ^ ^ ^ ^ ^ i 
B. M 1 2 3 4 5 6 N 
603 b p _ ^ ^ M | | H ^ ^ ^ ^ ^ ^ ^ | 
^ b p i H 
C. M 1 2 3 4 5 6 N 
603 b p _ J j J ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ H 
^ W M 
Fig. 5. Optimisation ofannealing temperature for MY09MY11 PCR 
PCR with primer concentration at 0.25 mM. Annealing temperatures 
used were (A) 53^C, (B) 55。C，(C) 57。C. 
Lanes: M, Marker 0-174-RF DNA digested by Hae III; 
1-6’ RecombinantHPV16 (pHPV16) DNAs dilutedto 10^, 10\ 
W’ 10】，10】，10^ copies/5-jj,l inoculum with 1 ng/pil of salmon sperm DNA; 
N, Double distilled water as negative control. 
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A. i ii 
M 1 2 3 4 N 1 2 3 4 
^ ^ ^ m m 
603 h p _ J K ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ M 
b p _ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ H 
^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^H 
B. i ii 
M 1 2 3 4 N 1 2 3 4 
603 b p _ ^ H j ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ | 
i ^ H 
Fig. 6. Optimisation ofprimer concentration for MY09/MY11 PCR 
with annealing temperature at 55®C. Primer concentrations used were 
(A.i) 1 mM，(A.ii) 0.5 mM; (B.i) 0.25 mM，(B.ii) 0.125 mM. 
Lanes: M, Marker 0-174-RF DNA digested by Hae III; 
1-4，Recombinant HPV 16 (pHPV 16) DNAs diluted to 10\ 10\ 
102，iQi copies/5-fil inoculum with 1 ng/jul of salmon sperm DNA; 
N, Double distilled water as negative control 
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A. M 1 2 3 4 5 6 N 
» • 
B M 1 2 3 4 5 6 N 
-^ ^^ 1 
C M 1 2 3 4 5 6 N 
234 b p _ ^ Q ^ | ^ H ^ ^ | 
Fig. 7. Optimisation ofannealing temperature for GP5+/GP6+ PCR 
with primer concentration at 0.25 mM. Annealing temperatures 
used were (A) 43。C，(B) 45。C，(C) 4TC. 
Lanes: M，Marker 0-174-RF DNA digested by Hae III; 
1-6’ Recombinant HPV 16 (pHPV 16) DNAs diluted to 10^, 10\ 
10^ 102’ jQi^ jQO copies/5-jil inoculum with 1 ng/jxl of salmon sperm DNA; 
N, Double distilled water as negative control 
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A. i ii 
M 1 2 3 4 N 1 2 3 4 
b p _ J P ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ | 
"""^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^H 
310 h p _ J ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ M 
^^^^^^^^^^^^^^^^m 
B. i ii 
M 1 2 3 4 N 1 2 3 4 
b p _ J H ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ | 
*""~^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^g 
310 h p _ J ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ M 
Fig. 8. Optimisation ofprimer concentration for GP5+/GP6+ PCR 
with annealing temperature at 45®C. Primer concentrations used 
were (A.i) 1 mM, (A.ii) 0.5 mM; (B.i) 0.25 mM，(B.ii) 0.125 mM. 
Lanes: M’ Marker 0-174-RF DNA digested by Hae III; 
1-4’ Recombinant HPV 16 (pHPV 16) DNAs diluted to 10^, 
JO^’ I0^, 10^ copies/5-|jil inoculum with 1 ng/jxl of salmon sperm DNA; 
N，Double distilled water as negative control 
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Fig. 9. Intensity ofbeta-globin PCR amplicons for PC03/PC07 
PCR (509 bp) and Beta-GPl/Beta-GP2 PCR (355 bp). 
Intensity range from 1+ (Lanes 1 and 3)，2+ (Lanes 2 and 4) 
and 3+ (Lanes 5 and 6). 
Lanes: M，Marker 0-174-RF DNA digested by Hae III; 
1 and 4，DNA extracted by Pheonl-Chloroform; 
2 and 5, DNA extracted by Microwave; 
3 and 6’ DNA extracted by QIAGENspin column; 
N, Double distilled water as negative control 
99 
M 1 2 3 4 5 6 N 7 
^ | ^ H 
b p _ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ m ^ ^ ^ ^ ^ ^ m i 
^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ j 
310 hp_J^K^^^^^^^^^^^^^^^^^^^M 
Fig. 10. PC03/PC07 PCR amplification ofcervical biopsies. 
Lanes: M，Marker 0-174-RF DNA digested by Hae III; 
1 and 4’ DNA extracted by QIAGENspin column; 
2 and 5, DNA extracted by Microwave; 
3 and 6, DNA extracted by Pheonl-Chloroform; 
7，White blood cell lysate (10^ cells/5-pil inoculum) as positive controls; 
N’ Double distilled water as negative control 
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Fig. 11. Beta-GPl/Beta-GP2 PCR amplification of cervical biopsies. 
Lanes: M，Marker 0-174-RF DNA digested by Hae III; 
1，4 and 7, DNA extracted by QIAGENspin column; 
2, 5 and 8’ DNA extracted by Microwave; 
3, 6 and 9, DNA extracted by Pheonl-Chloroform; 
10，White blood cells (10^cells/5-fd inoculum) as positive controls; 
N, Double distilled water as negative control 
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Fig. 12. MY09MY11 PCR amplification ofcervical 
scrape samples from women with normal cervices, 
targeted for HPV L1 region (450 bp). 
Lanes: M，Marker 0-174-RF DNA digested by Hae III; 
1-4’ Patient samples; 
5 and 6’ pHPV 16 (1000 & 100 copies/5-/J inoculum) as positive controls; 
N，Double distilled water as negative control • 
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Fig. 13. MY09MY11 PCR amplification ofcervical 
scrape samples from women with abnormal cytologies, 
targeted for HPV L1 region (450 bp). 
Lanes: M’ Marker 0-174-RF DNA digested by Hae III; 
1-6, Patient samples; 
7 and 8, pHPV16 (1000 <^ 100 copies/5-jxl inoculum) as positive controls; 
N, Double distilled water as negative control 
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Fig. 14. MY09MY11 PCR amplification ofcervical biopsies 
samples targeted for HPV L1 region (450 bp). 
Lanes: M，Marker 0-174-RF DNA digested by Hae III; 
1-5，Patient samples; 
6 and 7, pHPV 16 (1000 & 100 copies/5-pil inoculum) aspositive controls; 
N’ Double distilled water as negative control. 
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Fig. 15. GP5+/GP6+ PCR amplification ofcervical biopsies 
samples targeted for HPV L1 region (150 bp). 
Lanes: M’ Marker 0-174-RF DNA digested by Hae III; 
1-3, Patient samples; 
4 and 5, pHPV 16 (1000 & 100 copies/5-fil inoculum) as positive controls; 
N’ Double distilled water as negative control 
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Fig. 16. Restriction fragment length polymorphisms of 
HPV genotypes obtained by endonuclease digestion of 
MY09MY11 PCR products (I). 
Lanes: M’ Marker 25 bp DNA Ladder; 
1，HPV6b undigested; 
2、HPV 6b digested with Rsa I; 
3, HPV 6b digested with Dde I; 
4，HPV11 undigested; 
5, HPV11 digested with Rsa I： 
6, HPV11 digested with Dde I; 
7, HPV16 undigested; 
8, HPV16 digested with Rsa I; 
9, HPV 16 digested with Dde I; 
10’ HPVl8undigested; 
11, HPV 18 digested with Rsa I; 
12，HPV 18 digested with Dde I; 
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Fig. 17. Restriction fragment length polymorphisms of 
HPV genotypes obtained by endonuclease digestion of 
MY09MY11 PCR products (11). 
Lanes: M，Marker 25 bp DNA Ladder; 
7, HPV31 undigested; 
2, HPV 31 digested with Rsa I; 
5, HPV31 digested with Dde I; 
4, HPV33 undigested; 
5, HPV33 digestedwith Rsa I; 
6,HPV23 digested with Dde I; 
7’ HPV52 undigested; 
8，HPV52 digested with Rsa I; 
9, HPV52 digested with Dde I; 
10, HPV58 undigested; 
11’ HPV58 digested with Rsa I; 
12’ HPV58 digestedwith Dde I; 
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Fig. 18. Restriction fragment length polymorphisms of 
HPV genotypes obtained by endonuclease digestion of 
MY09MY11 PCR products of cervical scrape samples 
from women with normal cervices. 
Lanes: M’ Marker 25 bp DNA Ladder; 
1，HPV16undigested; 
2,HPV 16 digested with Rsa I; 
3, HPV 16 digested with Dde I; 
4, HPV52 undigested; 
5, HPV 52 digested with Rsa I;; 
6’ HPV 52 digested with Dde I; 
7’ HPV53 undigested; 
8, HPV53 digested with Rsa I; 
9, HPV53 digested with Dde I; 
10，uncharacterized HP V undigested; 
11’ uncharacterizedHPVdigested with Rsa I; 
12，uncharacterized HPVdigested with Dde I; 
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Fig. 19. Optimisation ofannealing temperature for HPV 16 E7 outer 
PCR with primer concentration at 0.25 mM. Annealing temperatures 
used were (A) 53"C, (B) 55"C, (C) 5TC. 
Lanes: M’ Marker 0-174-RF DNA digested by Hae III; 
1-6, RecombinantHPV16 (pHPV16) DNAs dilutedto 10^ 10\ 
10^’ 102’ JO】,]Q0 copies/5-jul inoculum with 1 wg//z/ of salmon sperm DNA; 
N, Double distilled water as negative control 
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Fig. 20. Optimisation ofprimer concentration for HPV 16 E7 outer 
PCR with annealing temperature at 5TC. Primer concentrations used 
were (A.i) 1 mM, (A.ii) 0.5 mM; (B.i) 0.25 mM, (B.ii) 0.125 mM. 
Lanes: M’ Marker 0-174-RF DNA digested by Hae III; 
1-4，Recombinant HPV 16 (pHPV16) DNAs diluted to 10^ 
10^, 102，jQj copies/5'pd inoculum with 1 ng/jd of salmon sperm DNA; 
N, Double distilled water as negative control 
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Fig. 21. Optimisation ofannealing temperature for HPV 16 E7 
inner PCR with primer at 0.25 mM. Annealing temperatures used 
were (A) 53"C, (B) 55。C，(C) 57 "C. 
Lanes: M, Marker 0'174-RF DNA digested by Hae III; 
1-6’ Recombinant HPV 16 (pHPV 16) DNAs diluted to 10^, I0^, 
10\ 102，iQi^ jQO copies/5'fil inoculum with 1 ng/fil of salmon sperm DNA; 
N，Double distilled water as negative control 
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Fig. 22. Optimisation ofprimer concentration for HPV 16 E7 inner 
PCR with annealing temperature at 57®C. Primer concentrations used 
were (A.i) 1 mM，(A.ii) 0.5 mM; (B.i) 0.25 mM，(B.ii) 0.125 mM. 
Lanes: M, Marker 0'174-RF DNA digested by Hae III; 
1-4’ Recombinant HPV 16 (pHPV 16) DNAs diluted to 10^ 
I0^, 10^, lQi copies with 1 ng/fil ofsalmon sperm DNA; 
N，Double distilled water as negative control 
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Fig. 23. Purified HPV 16 E7 nested PCR products. 
Lanes: M，Marker 0-174-RF DNA digested by Hae III; 
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